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1.1.	  Sirtuins,	  a	  unique	  class	  of	  lysine	  deacetylases	  
During	  the	  last	  decade,	  the	  members	  of	  the	  Sir2	  family,	  also	  known	  as	  sirtuins,	  
have	  become	  firmly	  established	  as	  key	  regulators	  of	  the	  response	  to	  stress	  of	  
various	   types,	   from	   metabolic	   to	   genotoxic	   stress.	   Sirtuins	   have	   been	  
implicated	   in	   the	   most	   important	   human	   diseases	   such	   as	   cancer,	  
cardiovascular	   diseases,	   diabetes	   and	   other	   endocrine	   pathologies,	   malaria,	  
and	  neurodegenerative	  diseases,	  among	  others1;	  2.	  
Sirtuins	   were	   originally	   described	   as	   NAD+-­‐dependent	   histone	   deacetylases3	  
and	  were	   included	   in	  the	  superfamily	  of	  histone	  deacetylase	   (HDAC)	  enzymes	  
as	  class	  III	  HDACs.	  In	  fact,	  there	  are	  4	  classes	  of	  HDACs:	  class	  I	  (HDAC1,	  2,	  3,	  and	  
8),	  which	   are	   closely	   related	   to	   the	   yeast	   transcriptional	   factor	   RPD3;	   class	   II	  
(HDAC4,	   5,	   6,	   7,	   9,	   and	   10),	   which	   are	   similar	   to	   another	   yeast	   deacetylase	  
HDA1;	   class	   III,	   which	   includes	   sirtuins;	   and	   class	   IV	   (HDAC11).	   Indeed,	   the	  
process	   of	   deacetylation	   differs	   markedly	   between	   sirtuins	   and	   all	   other	  
HDACs.	  While	   class	   I,	   II,	   and	   IV	   HDACs	   transfer	   the	   final	   acetyl	   group	   to	   the	  
aqueous	  solution	  and	  are	  sensitive	  to	  the	  inhibitor	  trichostatin	  A	  (TSA),	  sirtuins	  
require	   NAD+	   as	   an	   enzymatic	   co-­‐factor,	   transfer	   the	   acetyl	   group	   from	   the	  
substrate	  to	  an	  ADP-­‐ribose	  molecule,	  and	  are	  insensitive	  to	  TSA4.	  Interestingly,	  
ADP-­‐ribosyltransferase	   activity	   is	   also	   known	   in	   sirtuins,	   although	   our	  
knowledge	  about	  this	  is	  currently	  very	  limited5;	  6.	  
The	   members	   of	   the	   Sir2	   family	   have	   been	   present	   since	   they	   evolved	   in	  
prokaryotes.	   They	   have	   subsequently	   undergone	   considerable	   functional	  
diversification	   during	   the	   course	   of	   evolution	   in	   order	   to	   adapt	   to	   increased	  
complexities.	   For	   instance,	  mammals	   harbor	   7	   different	   sirtuins	   (SIRT1-­‐SIRT7)	  
that	   differ	   in	   their	   cellular	   localization,	   substrate	   specificity,	   and	   functions7.	  
Sirtuins	  seem	  to	  have	  developed	  in	  some	  types	  of	  bacteria	  as	  regulators	  of	  the	  
metabolic	   adaptation	   to	   energetic	   fluctuations.	   Although	  we	   do	   not	   yet	   fully	  
understand	  all	  the	  implications	  of	  sirtuin	  functions	  in	  prokaryotes,	  their	  ability	  
to	  deacetylate	  proteins	  may	  have	  first	  appeared	  as	  a	  mechanism	  to	  catabolize	  
acetate	   before	   adapting	   specifically	   to	   perform	   regulatory	   functions.	   In	   this	  
sense,	  one	  of	  the	  best-­‐conserved	  sirtuin	  functions	  is	  the	  regulation	  of	  the	  inter-­‐	  
mediate	  metabolism	  through	  control	  of	  the	  key	  enzyme	  acetyl–CoA	  synthetase	  
(ACS).	  The	  Sir2	  family	  members	  encompass	  all	  the	  main	  phylogenetic	  domains	  
of	   living	   organisms,	   bacteria,	   archaea	   and	   eukaryotes,	   although	   not	   all	  
prokaryotes	  contain	  sirtuins.	  Phylogenetic	  studies	  have	  defined	  five	  lineages	  or	  
classes	  of	   sirtuins:	   classes	   I	   to	   IV	  and	  U8.	  The	  seven	  mammalian	  sirtuin	  genes	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include	  all	  four	  classes:	  SIRT1,	  SIRT2,	  and	  SIRT3	  are	  class	  I,	  SIRT4	  is	  class	  II,	  SIRT5	  
is	  class	  III,	  and	  SIRT6	  and	  SIRT7	  are	  class	  IV.	  Prokaryotes	  and	  eukaryotes	  share	  
only	  classes	  II	  and	  III.	  Consistent	  with	  this,	  the	  eukaryotic	  members	  of	  classes	  II	  
and	   III	   show	   mitochondrial	   localization	   and	   target	   mitochondrial	   proteins.	  
Interestingly,	   the	   two	   eukaryote-­‐specific	   lineages	   (I	   and	   IV)	   seem	   to	   have	  
appeared	  in	  early	  eukaryotes	  probably	  at	  the	  same	  time	  as	  chromatin.	  	  
The	   number	   of	   sirtuins	   per	   organism	   appears	   to	   have	   increased	   during	  
evolution	   along	   with	   complexity,	   from	   the	   presence	   of	   1	   member	   in	  
prokaryotes	  to	  2	   in	  Plasmodium,	  4	   in	  Caenorhabditis	  elegans,	  6	   in	  Drosophila,	  
and	   7	   in	   mammals.	   This	   probably	   reflects	   a	   constant	   dynamic	   acquisition	   of	  
new	   functions	   associated	   with	   the	   response	   of	   metabolic	   homeostasis	   to	  
different	  types	  of	  stress.	  Since	  the	  evolution	  of	  the	  prokaryotes,	  sirtuins	  seem	  
to	  have	  been	  involved	  in	  the	  crosstalk	  between	  the	  genome	  and	  environmental	  
changes.	   The	   functional	   diversification	   of	   Sir2	   homologs	   during	   evolution	   is	  
clearly	   illustrated	   by	   their	   different	   cellular	   locations9.	   Three	   of	   them	   (SIRT1,	  
SIRT6,	   and	   SIRT7)	   are	   clearly	   localized	   in	   the	   nuclear	   compartment;	   in	  
particular,	  SIRT7	  is	  mostly	  restricted	  to	  the	  nucleolar	  region.	  However,	  SIRT1	  is	  
known	  to	  shuttle	  to	  the	  cytoplasm10;	  11.	  Meanwhile,	  SIRT3	  to	  SIRT5	  proteins	  are	  
mitochondrial	   proteins	   with	   well-­‐known	   mitochondrial	   substrates,	   although	  
full-­‐length	  SIRT3	  is	  also	  found	  in	  the	  nucleus	  under	  normal	  conditions12.	  SIRT2	  
is	  the	  only	  mammalian	  sirtuin	  localized	  mainly	  in	  the	  cytoplasm,	  although	  it	  has	  
been	  found	  to	  translocate	  to	  the	  nucleus	  during	  G2/M	  transition13	  and	  during	  
bacterial	  infection14.	  	  
	  
	  
1.1.1.	  Structure	  and	  enzymatic	  activity	  
The	  high	  degree	  of	  conservation	  among	  Sir2	  family	  members	  between	  bacteria	  
and	  humans	   is	   restricted	   to	   their	   catalytic	  domain,	   a	   region	  of	   approximately	  
250	  residues15.	  Eukaryotic	  sirtuins	  have	  developed	  amino	  (N)–	  and	  carboxy	  (C)–
terminal	  extensions	  that	  are	  divergent	  among	  the	  members	  of	  the	  family16	  and	  
that	   have	   allowed	   the	   acquisition	   of	   specific	   new	   functions	   and	   substrates	  
during	   evolution.	   This	   variety	   of	   terminal	   regions	   has	   been	   proposed	   as	  
explaining	   the	   diversity	   of	   sirtuin	   functions,	   including	   the	   regulation,	  
recruitment,	  and	  differential	  activity	  of	  each	  of	  the	  family	  members17.	  The	  Sir2	  
family	  structure	  is	  based	  on	  an	  NAD+	  binding	  Rossmann-­‐fold	  domain	  and	  a	  Zn2+	  
binding	   domain.	   The	   catalytic	   site	   is	   situated	   inside	   a	   hydrophobic	   channel	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formed	  between	  these	  two	  binding	  domains,	  so	  that	  the	  end	  of	  the	  acetyllysine	  
chain	   is	   located	   close	   to	   the	   nicotinamide	   ribose	   of	   NAD+18.	   As	   expected,	  
mutations	   in	   the	   conserved	   residues	   along	   the	   NAD+	   binding	   domain	   disrupt	  
HDAC	  activity19.	  However,	  in	  contrast	  to	  other	  classes	  of	  HDACs,	  Zn2+	  does	  not	  
have	  a	  catalytic	  function	  but	  a	  structural	  role.	  The	  mechanistic	  similarities	  and	  
significant	   conservation	   of	   the	   catalytic	   domain	   between	   sirtuins	   and	   the	  
superfamily	   of	   poly	   (ADP-­‐ribose)	   polymerases	   (PARPs)	   strongly	   suggest	   that	  
sirtuins	  are	  directly	  related	  to	  these	  enzymes.	  	  
One	   of	   the	   most	   important	   aspects	   of	   sirtuin	   biology	   is	   the	   dual	   enzymatic	  
nature	   of	   the	   family.	   Sirtuins	   harbor	   two	   types	   of	   related	   enzymatic	   activity:	  
deacetylase	   activity,	   which	   in	   some	   metabolic	   contexts	   can	   also	   be	   defined	  
more	   generally	   as	   a	   deacylase	   activity20;	   21,	   and	  mono-­‐ADP-­‐ribosyltransferase	  
(ADPRT)	  activity.	  Both	  appear	  to	  derive	  from	  the	  general	  enzymatic	  reaction	  of	  
sirtuins,	  proposed	  by	  Sauve	  et	  al.	   in	  200122	  (Figure	  1).	  First,	  the	  enzyme	  binds	  
to	  NAD+	   in	  the	  presence	  of	  a	  substrate.	  Second,	   it	  breaks	  the	  NAD+	  molecule,	  
releasing	  nicotinamide	  and	  retaining	  the	  resulting	  ADP-­‐ribose	  molecule.	  Third,	  
in	   the	   case	  of	   deacetylation,	   the	  enzyme	   transfers	   the	   acetyl	   group	   from	   the	  
substrate	  to	  the	  ADP-­‐ribose	  molecule,	  releasing	  O-­‐acetyl-­‐ADP-­‐ribose	  (OAADPr).	  
Alternatively,	   the	   ADP-­‐ribosyltransferase	   is	   active	   when,	   similarly	   to	   what	  
occurs	   with	   PARPs,	   the	   sirtuin	   enzyme	   transfers	   the	   ADP-­‐ribose	  molecule	   to	  
another	   protein.	   The	   OAADPr	   molecules	   generated	   in	   the	   deacetylation	  
reaction	   are	   themselves	   a	   potential	   second	   messenger.	   The	   exact	   molecular	  
functions	   of	   OAADPr	   remain	   elusive,	   although	   studies	   have	   suggested	   that	  
OAADPr	  promotes	  pathways	  that	  suppress	  ROS	  accumulation.	  
At	   present,	   we	   do	   not	   completely	   understand	   the	   nature	   of	   this	   catalytic	  
duality.	  Our	  current	  knowledge	  suggests	  that	  the	  preeminence	  of	  any	  of	  these	  
activities	  or	  the	  existence	  of	  both	   in	  a	  given	  sirtuin	  may	  be	  related	  to	  specific	  
differences	   between	   lineages.	   For	   instance,	   the	   best-­‐studied	   class	   II	   sirtuin,	  
SIRT4,	  appears	  to	  be	  mainly	  an	  ADP-­‐ribosyltransferase,	  while	  the	  vast	  majority	  
of	   class	   I	   sirtuins,	   such	   as	  mammalian	   SIRT1	   to	   SIRT3	   or	   yeast	   sirtuins,	   show	  
robust	  deacetylase	  activity.	  Evidence	  suggests	  that	  class	  III	  and	  IV	  sirtuins	  may	  
generally	   exhibit	   both	   activities	   (SIRT6,	   pfSir2A,	   CobB),	   depending	   on	   the	  
substrate	   and	   functional	   context.	   However,	   given	   our	   currently	   limited	  
knowledge	   of	   sirtuin	   substrates	   outside	  mammals,	   these	   conclusions	   are	   not	  
definitive	   and	   will	   require	   periodic	   reconsideration.	   For	   instance,	   we	   cannot	  
rule	   out	   the	   possibility	   that	   all	   sirtuins	  may	   harbor	   both	   enzymatic	   activities,	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using	   one	   or	   the	   other	   in	   different	   contexts	   and	   with	   the	   appropriate	  
substrates.	  Some	  groups	  have	  suggested	  that	  this	  general	  activity	  is	  more	  likely	  
to	   be	   an	   inefficient	   side	   effect	   associated	   with	   the	   deacetylase	   activity6.	  
However,	   the	   fact	   that	   an	   acetylated	   residue	   is	   not	   required	   for	   ADPRT	  
activity23	  and	  that	  certain	  point	  mutations	  in	  the	  conserved	  catalytic	  domain	  of	  
SIRT6	  can	  stop	  its	  deacetylation	  activity	  without	  altering	  its	  ADPRT	  activity	  and	  
viceversa24,	  suggests	  that	  the	  two	  enzymatic	  activities	  are	  different.	  This	  matter	  
is	  still	  open	  to	  debate.	  
Some	   recent	   studies	   have	   also	   revealed	   a	   previously	   unknown	   enzymatic	  
activity	   that	   recall	   the	   original	   direct	   involvement	   of	   sirtuins	   in	   metabolism:	  
long-­‐chain	  deacylation.	  The	  mitochondrial	  SIRT5	  was	   identified	  as	  an	  efficient	  
desuccinylase	  and	  demalonylase20,	  and	  the	  removal	  of	  a	  myrystoil	  group	  from	  
the	   tumor	   necrosis	   factor-­‐α	   (TNF-­‐α)	   in	   the	   endoplasmic	   reticulum	   was	  
attributed	   to	  SIRT621.	   Long-­‐chain	  deacylation	  was	   later	   identified	  as	  a	  general	  
feature	   of	   most	   mammalian	   sirtuins,	   ranging	   from	   SIRT1	   to	   SIRT625.	   The	  
activation	  mechanism	  is	  consistent	  with	  fatty	  acid	  inducing	  a	  conformation	  that	  
binds	   acetylated	   H3	   with	   greater	   affinity.	   Consistent	   with	   this,	   several	  
biologically	   relevant	   free	   fatty	   acids,	   including	   myristic	   acid,	   at	   physiological	  
concentrations	   induced	  up	   to	  a	  35-­‐fold	   increase	   in	  deacetylation	  efficiency	  of	  
SIRT6	  on	  H3K9Ac	  peptides25.	  	  
Sirtuins	  were	  originally	  identified	  in	  1996,	  as	  ADP-­‐ribosyltransferases,	  when	  the	  
Salmonella	   typhimurium	   protein	   CobB	   was	   found	   to	   compensate	   for	   the	  
absence	  of	   CobT	   in	   the	   synthesis	   of	   cobalamin	   (vitamin	  B12).	   In	   2000,	  NAD+-­‐
dependent	   histone	   deacetylase	   activity	   was	   reported	   in	   yeast	   Sir2p,	   the	  
founding	  member	  of	  the	  family,	  and	  was	  shown	  to	  be	  essential	  for	  the	  role	  of	  
Sir2p	   in	  silencing26.	  With	  the	  study	  of	  the	  mammalian	  members	  of	  the	  family,	  
SIRT1	   to	  SIRT7,	   it	   soon	  became	  clear	   that	   sirtuin	  deacetylase	  activity	  was	  not	  
restricted	   to	   histones,	   encompassing	   a	   whole	   new	   world	   of	   non-­‐histone	  
substrates.	  The	   first	  of	   these	  substrates,	   identified	   for	  mammalian	  SIRT1,	  was	  
the	  tumor	  suppressor	  p53.	  Since	  then,	  the	  list	  of	  non-­‐histone	  substrates	  of	  the	  
members	   of	   the	   family	   has	   grown	   so	   long	   to	   include	   metabolic	   enzymes,	  
chromatin	  machinery	   factors,	  key	  transcription	   factors,	  cytoskeleton	  subunits,	  
and	  many	   others.	   A	   puzzling	   aspect	   of	   sirtuin	   activity	   is	   that	   there	   does	   not	  
seem	  to	  be	  a	  defined	  consensus	  sequence	  in	  the	  regions	  they	  target,	  as	  a	  group	  
or	  individually.	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Figure	  1.	  Sirtuin	  catalytic	  mechanisms	  (Michan	  S	  and	  Sinclair	  D,	  Biochem	  J	  2007).	  
	  
	  
1.1.2.	  Sirtuin	  chromatin	  regulators	  
Despite	   its	   prokaryotic	   origin,	   the	   development	   of	   chromatin	   in	   eukaryotes	  
appears	   to	   have	   been	   a	   milestone	   in	   sirtuin	   history,	   since	   they	   underwent	  
major	   adaptation	   that	   enabled	   them	   to	   signal	   stress	   conditions	   to	   the	  
genome26.	  For	  this	  purpose,	  two	  new	  lineages	  intimately	  related	  to	  chromatin,	  
classes	  I	  and	  IV,	  seem	  to	  have	  arisen	  in	  the	  early	  stages	  of	  eukaryote	  evolution.	  
The	  functions	  regulated	  by	  this	  “chromatin	  adaptation”	  range	  from	  the	  control	  
of	   metabolism	   homeostasis	   and	   survival	   upon	   stress	   to	   the	   protection	   of	  
genome	   stability.	   Sirtuins	   perform	   these	   chromatin	   functions	   through	   three	  
mechanisms.	  
The	   main	   mechanism	   involves	   the	   transcriptional	   silencing	   of	   a	   particular	  
region,	  which	  may	  encompass	  a	  single	  gene,	  a	  defined	  set	  of	  genes,	  or	  a	  whole	  
locus.	   In	   most	   of	   the	   cases	   studied,	   the	   silencing	   established	   by	   sirtuins	   is	  
epigenetic	   and	   involves	   the	   formation	   of	   compacted	   heterochromatin	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structures.	   Two	   loci	   have	   been	   found	   to	   be	   consistently	   epigenetically	  
regulated	  by	  sirtuins	  in	  early	  eukaryotes	  onwards:	  nucleolar	  rDNA	  transcription	  
and	   subtelomeric	   regions.	   Both	   seem	   to	   reflect	   functional	   adaptations	   of	  
sirtuins	   for	   regulating	  different	   types	  of	   stress	   through	  chromatin.	   In	   the	   first	  
case,	  it	  appears	  to	  be	  linked	  to	  the	  response	  to	  metabolic	  and	  energetic	  stress	  
in	  order	  to	  control	  ribosome	  expression	  and	  thereby	  protein	  production.	  This	  is	  
a	   very	   significant	   regulatory	   process	   since	   it	   is	   an	   energetically	   expensive	  
process	   that	   is	   key	   to	   regulating	   proliferation.	   The	   second	   case,	   the	  
subtelomeric	   region,	   is	   mainly	   related	   to	   genotoxic	   stress	   and	   is	   directly	  
associated	  with	   a	   second	   conserved	  mechanism	   of	   sirtuins	   in	   chromatin:	   the	  
regulation	   of	   chromatin	   structure	   and	   organization	   in	   order	   to	   maintain	  
genome	   stability.	   The	   most	   obvious	   cases	   are	   the	   conserved	   regulation	   of	  
telomere	  structure	  by	  sirtuins	  from	  unicellular	  protozoa	  and	  yeast	  to	  humans.	  
Sirtuins	  have	  also	  adapted	  to	  regulate	  the	  other	  great	  structural	  chromosomal	  
region	  or	  constitutive	  heterochromatin,	  the	  pericentromeric	  area.	  Constitutive	  
heterochromatin	   refers	   to	   the	  regions	   that	   tend	  to	  have	  a	  structural	   role	  and	  
never	   decompact,	   such	   as	   centromeres	   and	   telomeres,	   in	   contrast	   to	  
facultative	   heterochromatin,	   which	   corresponds	   to	   regions	   that	   can	   be	  
compacted	   in	   response	   to	   certain	   programs	  or	   stimuli,	   such	   as	   development,	  
stress	   response,	   or	   differentiation,	   and	   that	   can	   decompact	   when	   required.	  
Thus,	   in	   fission	  yeast	  S.	  pombe	  and	  mammals,	  spSir2p	  and	  SIRT1	  are	  required	  
for	   the	   formation	   and	   maintenance	   of	   pericentromeric	   heterochromatin	  
structure27.	   Another	   functional	   aspect	   closely	   associated	   with	   the	   role	   of	  
sirtuins	  in	  protecting	  genome	  integrity	  is	  their	  conserved	  role	  in	  signaling	  DNA	  
damage	   and	   DNA	   repair,	   as	   we	   discuss	   below.	   Finally,	   another	   interesting	  
aspect	  of	  sirtuins	  in	  chromatin	  is	  associated	  with	  the	  global	  control	  of	  cell	  cycle	  
progression,	  as	  has	  been	  shown	  for	  mammalian	  SIRT2.	  
Sirtuin	   chromatin-­‐associated	   functions	   are	   largely	   realized	   through	   the	  
modulation	   of	   epigenetic	   information	   by	   direct	   deacetylation	   of	   specific	  
histone	   acetylation	   marks	   (Figure	   2).	   In	   this	   regard,	   two	   modifications	   have	  
been	  widely	   conserved	   during	   evolution	   and	   are	   functionally	   relevant	   to	   the	  
function	   of	   sirtuins:	   acetylation	   of	   histone	   H4	   in	   lysine	   16	   (H4K16Ac)	   and	  
acetylation	  of	  histone	  H3	  in	  lysine	  9	  (H3K9Ac).	  
H4K16Ac	   has	   exclusive	   properties	   due	   to	   its	   unique	   role	   in	   regulating	   chro-­‐	  
matin	   structure26.	   Its	   presence	   inhibits	   the	   folding	   of	   the	   chromatin	   fiber	   in	  
vitro	   and	   therefore,	   as	   has	   been	   suggested,	   also	   inhibits	   the	   formation	   of	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higher	   orders	   of	   chromatin	   compaction.	   Acetylation/deacetylation	   of	   H4K16	  
has	   been	   associated	  with	   epigenetic	   phenomena	   throughout	   evolution,	   from	  
silencing	   in	   S.	   cerevisiae,	   through	   X-­‐chromosome	   dosage	   compensation	   in	  
Drosophila,	   to	   silencing	   in	   mammals.	   H4K16Ac	   has	   also	   been	   linked	   to	   the	  
regulation	   of	   cell	   cycle	   progression,	   transcription,	   DNA	   repair,	   and	   DNA	  
replication.	   Moreover,	   hypoacetylation	   of	   H4K16	   has	   been	   proposed	   as	   a	  
hallmark	  of	  cancer.	  The	  functional	  link	  between	  sirtuins	  and	  H4K16Ac	  is	  mainly	  
restricted	  to	  the	  class	  I	  sirtuins,	  including	  yeast	  Sir2p	  and	  mammalian	  SIRT1	  to	  
SIRT312;	  28;	  29.	  
The	  behavior	  of	  the	  other	  silencing-­‐related	  mark,	  H3K9,	   is	  very	  different	  from	  
that	   of	   H4K16.	   Deacetylation	   of	   H3K9	   is	   a	   requirement	   for	   subsequent	  
methylation	   in	   the	   same	   residue,	  H3K9me2/3,	   a	   hallmark	  of	   higher	  orders	   of	  
chromatin	   compaction	   or	   heterochromatin	   conserved	   from	   amoeba	   to	  
humans.	   Among	  mammalian	   sirtuins,	   class	   I	   SIRT1	   and	   class	   IV	   SIRT6	   are	   the	  
most	   functionally	   important	   H3K9Ac	   deacetylases.	   SIRT6	   H3K9Ac	   deacetylase	  
activity	   is	   important	   for	   modulating	   telomere	   structure	   and	   DNA	   repair	   of	  
double-­‐strand	  breaks	  (DSBs)30;	  31.	  
In	   the	   case	   of	   mammalian	   SIRT1,	   deacetylation	   of	   H4K16Ac	   and	   H3K9Ac	   is	  
directly	   associated	  with	   the	   capacity	   of	   SIRT1	   to	   coordinate	   the	   formation	  of	  
constitutive	   and	   facultative	   heterochromatin.	   Mammalian	   SIRT3	   is	   mainly	   a	  
mitochondrial	   protein	   that	   acts	   as	   the	   primary	   mitochondrial	   lysine	  
deacetylase32.	  However,	   a	   small	   SIRT3	   subpopulation	   localizes	   in	   the	  nucleus,	  
where	   it	   participates	   in	   the	   repression	   of	   key	   stress-­‐related	   genes	   through	  
deacetylation	  of	  their	  promoters	  in	  H3K9Ac	  and	  H4K16Ac12;	  33.	  It	  is	  of	  particular	  
note	   that	  H4K16Ac	  deacetylation	  by	   SIRT2	   is	   related	   to	   cell	   cycle	   control	  and	  
not	  to	  heterochromatin	  formation.	  During	  G2/M	  transition,	  SIRT2	  is	  shuttled	  to	  
the	  nucleus,	  where	  it	  deacetylates	  H4K16Ac	  globally	  before	  entering	  mitosis29.	  
Recently,	  a	  newly	  identified	  modification	  involved	  in	  transcriptional	  regulation,	  
H3K18Ac,	   has	   been	   linked	   to	   another	   class	   IV	   sirtuin,	   SIRT734.	   SIRT7	  
deacetylation	   and	   the	   consequent	   silencing	   of	   a	   specific	   set	   of	   genes	   were	  
shown	  to	  be	  crucial	  for	  maintaining	  the	  transformed	  phenotype	  in	  cancer	  cells.	  
Additionally,	   the	   enrichment	   of	   SIRT7	   in	   nucleoli	   also	   underlines	   the	   positive	  
function	  of	  SIRT7	  activity	  in	  regulating	  RNA	  polymerase	  I	  transcription	  and	  cell	  
growth.	   Conversely	   to	   SIRT1,	   which	   silences	   rDNA	   by	   deacetylating	   H4K16Ac	  
and	   H3K9Ac,	   SIRT7	   binds	   directly	   to	   the	   RNA	   polymerase	   I	   complex35	   and	  
deacetylates	   the	   PolI	   subunit	   PAF5336,	   exerting	   a	   positive	   effect	   on	   rDNA	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transcription.	  In	  addition,	  H3K18	  has	  been	  recently	  shown	  to	  be	  a	  deacetylation	  
target	   of	   SIRT2.	   During	   infection	  with	   the	   bacterium	   Listeria	  monocytogenes,	  
the	   host	   SIRT2	   translocates	   to	   the	   nucleus	   in	   a	   manner	   dependent	   on	   the	  
bacterial	   factor	   InlB14.	   SIRT2	   associates	   with	   the	   transcription	   start	   site	   of	   a	  
subset	   of	   genes	   repressed	   during	   infection	   and	   deacetylates	   H3K18.	   Thus,	  
SIRT2-­‐mediated	   H3K18	   deacetylation	   plays	   a	   critical	   role	   during	   infection,	  
which	  reveals	  an	  epigenetic	  mechanism	  imposed	  by	  a	  pathogenic	  bacterium	  to	  
reprogram	  its	  host.	  
Sirtuins	   have	   also	   been	   linked	   to	   DNA	   damage	   signaling	   and	   DNA	   repair	  
through	  the	  deacetylation	  of	  another	  mark,	  H3K56Ac.	  This	   is	   involved	   in	  DNA	  
damage	   signaling	   during	   S	   phase	   and	   is	   targeted	   by	   mammalian	   SIRT637;	   38.	  
Mammalian	   SIRT1	   and	   SIRT2	   are	   also	   believed	   to	   deacetylate	   H3K56Ac	   upon	  
DNA	  damage.	  	  
Another	   interesting	   functional	   relationship	   between	   histones	   and	   sirtuins	  
involves	  the	  linker	  histone	  H1.	  Mammalian	  SIRT1,	  the	  ortholog	  of	  S.	  cerevisiae	  
Sir2p,	  has	  been	  shown	  to	  bind	  directly	  and	  deacetylate	  the	  histone	  H1	  isoform	  




Figure	  2.	  Sirtuin	  functions	  and	  targets	   in	  the	  cell	  with	  a	  focus	  on	  sirtuin	  chromatin–related	  
functions	  (Martinez-­‐Redondo	  et	  al.	  Genes	  Cancer	  2013).	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1.2.	  Emerging	  roles	  of	  SIRT7	  in	  cancer	  
SIRT7	   is	   possibly	   the	   least	   understood	   mammalian	   sirtuin,	   but	   has	   several	  
features	  that	  suggest	  it	  may	  have	  unique	  cellular	  functions	  that	  are	  important	  
for	   human	   disease,	   particularly	   cancer.	   First,	   SIRT7	   is	   a	   nuclear,	   chromatin-­‐
associated	  lysine	  deacetylase	  that	  selectively	  removes	  a	  specific	  histone	  mark,	  
acetylated	   H3K18	   (H3K18Ac),	   depletion	   of	   which	   is	   associated	   with	   highly	  
malignant	  cancers	  and	  poor	  patient	  prognosis34.	   In	  addition,	  SIRT7	   is	  enriched	  
in	  nucleoli9,	  sub-­‐nuclear	  structures	  that	  are	  the	  sites	  of	  ribosome	  assembly	  and	  
are	  increased	  in	  size	  and	  number	  in	  aggressive	  tumors39.	  Indeed,	  SIRT7	  impacts	  
on	  ribosome	  biogenesis	  through	  multiple	  mechanisms	  and	  may	  thereby	  play	  a	  
major	   role	   in	   supporting	   the	   high	   biosynthetic	   demands	   of	   cancer	   cells.	  
Through	  these	  and	  other	  functions,	  SIRT7	  is	  a	  central	  coordinator	  of	  epigenetic	  
and	  metabolic	  programs	  that	  support	  cancer	  progression.	  
	  
1.2.1.	  Reprogramming	  tumor	  suppressive	  gene	  expression	  by	  selective	  H3K18	  
deacetylation	  
Cancer	  cells	  exhibit	  epigenetic	  chromatin	  alterations	   in	  histone	  marks	  both	  at	  
the	   global	   genome	   level	   and	   at	   specific	   gene	   regulatory	   sequences.	   Clinico-­‐
pathological	  studies	  have	  shown	  that	  in	  tumor	  tissues,	  low	  levels	  of	  H3K18Ac,	  a	  
histone	  mark	  associated	  with	  transcriptional	  activation,	  correlate	  strongly	  with	  
cancer	   disease	   severity.	   Indeed,	   global	   hypoacetylation	   of	   H3K18	   can	   be	  
prognostic	   of	   aggressive	   cancer	   phenotypes,	   increased	   risk	   of	   cancer	  
recurrence,	   and	  poor	  patient	   survival40;	  41;	  42.	  H3K18Ac	  hypoacetylation	   is	   also	  
linked	   to	   epigenetic	   reprogramming	  during	  oncogenic	   transformation	  by	   viral	  
oncoproteins43;	   44.	   Thus,	   H3K18	   hypoacetylation	   is	   a	   potential	   biomarker	   for	  
advanced	   disease	   in	   human	   cancer,	   and	   changes	   in	   the	   genome-­‐wide	  
distribution	   of	   H3K18Ac	   are	   proposed	   to	   control	   epigenetic	   gene	   expression	  
programs	  that	  drive	  cancer	  progression.	  	  	  
Many	   lysine	  deacetylases	  are	   relatively	  promiscuous,	   and	  SIRT7	   stands	  out	   in	  
being	   highly	   selective	   for	   specific	   substrates	   and	   physiologic	   contexts.	   At	  
chromatin,	   SIRT7	   specifically	   deacetylates	   H3K18Ac,	   but	   not	   numerous	   other	  
histone	   acetylation	   sites34.	   At	   present,	   SIRT7	   is	   the	   only	   known	   H3K18Ac-­‐
specific	   deacetylase	  enzyme,	   and	   it	   plays	   an	  essential	   role	   in	   establishing	   the	  
genome-­‐wide	  landscape	  of	  H3K18Ac.	  SIRT7	  selectively	  deacetylates	  H3K18Ac	  at	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promoters	   of	   a	   network	   of	   genes	  with	  multiple	   links	   to	   tumor	   suppression34.	  
The	   spectrum	   of	   SIRT7	   target	   genes	   is	   defined	   in	   part	   by	   the	   interaction	   of	  
SIRT7	  with	  the	  sequence-­‐specific	  ELK4	  transcription	  factor	  (Figure	  3A),	  which	  is	  
implicated	   in	  prostate	  and	  other	  cancers.	  When	  SIRT7	   is	   inactivated	   in	  cancer	  
cells,	  H3K18	  hyperacetylation	   leads	  to	  up-­‐regulation	  of	  the	  tumor	  suppressive	  
gene	   network	   and	   reversal	   of	   essential	   cancer	   cell	   phenotypes	   that	   are	  
hallmarks	   of	   oncogenic	   transformation.	  Most	   strikingly,	   depletion	   of	   SIRT7	   is	  
sufficient	   to	   reduce	   the	   tumorigenicity	   of	   cancer	   cells	   in	   mouse	   xenograft	  
assays	   in	   vivo34;	   45.	   Thus,	   SIRT7	   plays	   a	   fundamental	   role	   in	   epigenetic	  
maintenance	  of	  the	  neoplastic	  state	  of	  cancer	  cells.	  	  
Another	   major	   category	   of	   SIRT7	   target	   genes	   consists	   of	   ribosomal	   protein	  
genes,	  which	  are	  transcriptional	  targets	  of	  the	  oncogene	  Myc34;	  46	   (Figure	  3A).	  
Dysregulated	   protein	   translation	   and	   mutations	   of	   individual	   ribosomal	  
proteins	  are	  linked	  to	  cancer	  in	  multiple	  settings47.	  In	  a	  recent	  study,	  Shin	  and	  
colleagues	   showed	   that	  by	  opposing	  Myc-­‐dependent	   expression	  of	   ribosomal	  
proteins,	  SIRT7	  plays	  an	  adaptive	  role	  in	  the	  Unfolded	  Protein	  Response	  (UPR)	  
to	  suppress	  ER	  stress46.	  This	  study	  focused	  primarily	  on	  ER	  stress	  and	  the	  UPR	  
in	   the	   context	   of	   liver	   pathology,	   where	   chronic	   ER	   stress	   in	   SIRT7-­‐deficient	  
mice	   leads	   to	   fatty	   liver	   disease.	   However,	   up-­‐regulation	   of	   the	   UPR	   is	   also	  
important	  in	  many	  cancers,	  where	  rapid	  cell	  growth	  and	  hypoxic	  conditions	  can	  
trigger	   ER	   stress.	   The	   UPR	   allows	   cancer	   cells	   to	   evade	   ER	   stress-­‐induced	  
apoptosis,	   in	   part	   by	   transiently	   reducing	   protein	   synthesis	   rates48.	   In	   this	  
context,	  SIRT7	  can	  prevent	  ER	  stress-­‐induced	  apoptosis	  of	  cancer	  cells	  in	  a	  Myc-­‐
dependent	   manner.	   Thus	   SIRT7-­‐mediated	   repression	   of	   ER	   stress	   through	  
control	   of	   ribosomal	   protein	   gene	   transcription	   might	   be	   an	   underlying	  
mechanism	  that	  promotes	  cancer	  cell	  survival	  and	  tumor	  progression.	  
It	   is	   likely	   that	   SIRT7	   also	   influences	   other	   cancer-­‐regulatory	   gene	   expression	  
pathways,	   perhaps	   in	   specific	   cancer	   cell	   types	   or	   tumor	   conditions.	   For	  
instance,	   Myc	   coordinates	   a	   broad	   transcriptional	   program	   that	   promotes	  
cancer	   cell	   proliferation,	   survival,	   and	   metabolism	   through	   many	   targets49.	  
SIRT7	   might	   co-­‐repress	   oncogenic	   Myc	   functions	   in	   such	   settings,	   with	  
potentially	   tumor	   suppressive	   effects.	   Other	   in	   vitro	   evidence	   suggests	   that	  
SIRT7	   might	   directly	   regulate	   genes	   that	   control	   cancer	   cell	   adaptations	   to	  
hypoxia,	  by	  possibly	   interacting	  with	   the	  hypoxia	   inducible	   factors	  HIF-­‐1a	  and	  
HIF-­‐2a50.	  Finally,	  SIRT7	  is	  proposed	  to	  inhibit	  signaling	  by	  the	  tumor	  suppressor	  
p53	   and	   its	   target	   gene	   p21.	   Increased	   p53	   acetylation	   and	   activity	   were	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observed	   in	   SIRT7-­‐deficient	   mouse	   cardiomyocytes,	   although	   there	   is	  
conflicting	  data	  on	  whether	  SIRT7	  deacetylates	  p53	  directly9;	  34;	  51.	  SIRT7	  might	  
also	   repress	   transcription	   at	   p53-­‐dependent	   promoters	   by	   H3K18Ac	  
deacetylation,	   or	   inhibit	   the	   p53	   pathway	   indirectly.	   For	   example,	   in	  
hepatocellular	   carcinoma	   cells,	   SIRT7	   is	   proposed	   to	   inhibit	   transcriptional	  
activation	  of	  p21	  through	  tumor	  suppressive	  microRNAs,	  miR-­‐125a-­‐5p	  and	  miR-­‐
125b45.	  In	  addition,	  up-­‐regulation	  of	  rRNA	  synthesis,	  which	  is	  induced	  by	  SIRT7	  
(see	  below),	  can	  promote	  proteasomal	  degradation	  of	  p5352.	  	  
In	  summary,	  much	  evidence	  indicates	  that	  SIRT7	  plays	  an	  important	  role	  in	  the	  
maintenance	  of	  epigenetic	  patterns	  of	  H3K18	  acetylation	  in	  cancer	  cells,	  which	  
in	   turn	   drive	   gene	   expression	   programs	   that	   stabilize	   the	   transformed	  
phenotypes	   of	   these	   cells.	   Future	   work	   should	   uncover	   additional	   pathways	  
through	   which	   SIRT7	   influences	   cancer	   cell	   epigenetics,	   through	   histone	  
deacetylation	  at	  chromatin	  or	  novel	  mechanisms53.	  
	  
	  
1.2.2.	  Nucleolar	  guardian	  of	  ribosome	  biogenesis	  and	  protein	  homeostasis	  
Nucleoli	  are	  factories	  where	  ribosomal	  RNA	  (rRNA)	  is	  expressed	  and	  assembled	  
with	  ribosomal	  proteins	  into	  ribosomal	  complexes.	  Metabolically	  active	  tumor	  
cells	   show	   dramatically	   increased	   nucleolar	   size	   and	   number,	   which	   support	  
the	   increased	   protein	   synthesis	   requirements	   of	   these	   cells39.	   Indeed,	  
enhanced	  rRNA	  synthesis	  is	  now	  proposed	  to	  be	  an	  essential	  hallmark	  of	  cancer	  
cells54.	   Early	   studies	   showed	   that	   SIRT7	   is	   enriched	   in	   nucleoli,	   where	   it	  
associates	   with	   PolI	   and	   rDNA	   sequences	   (Figure	   3B).	   This	   finding	   was	  
intriguing,	  because	  yeast	  Sir2p	  also	  localizes	  to	  rDNA	  in	  nucleoli,	  and	  one	  of	  its	  
central	  functions	   is	  to	  suppress	  rDNA	  transcription	  by	  histone	  deacetylation55.	  
Surprising,	   however,	   SIRT7	   was	   found	   to	   activate,	   not	   repress,	   rDNA	  
transcription56.	   Moreover,	   reduced	   rRNA	   synthesis	   in	   SIRT7-­‐depleted	   cancer	  
cells	   was	   associated	   with	   decreased	   cell	   viability	   and	   proliferation56.	   This	  
observation	   suggested	   that	   increased	   SIRT7	   activity	   in	   cancer	   cells	  might	   fuel	  
tumor	  growth	  by	  promoting	  rRNA	  synthesis	  and	  ribosome	  biogenesis.	  
The	   effect	   of	   SIRT7	   on	   rRNA	   synthesis	   depends	   on	   an	   intact	   SIRT7	   catalytic	  
domain,	  but	   the	  molecular	   substrate	  of	   SIRT7	   in	   this	   context	  was	  not	   initially	  
clear.	   Indeed,	   histone	  deacetylation	  by	   SIRT7	  would	  have	   the	  opposite	   effect	  
on	   rDNA	   transcription.	   Recent	   findings	   now	   reveal	   that	   SIRT7	   can	   control	  
transcription	   of	   rDNA	   through	   deacetylation	   of	   a	   new	   substrate,	   the	   PAF53	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subunit	   of	   PolI,	   which	   facilitates	   recruitment	   of	   PolI	   to	   rDNA	   sequences36	  
(Figure	   3B).	   Additional	   protein	   interactions	   of	   SIRT7	   with	   several	   nucleolar	  
chromatin	   remodeling	   complexes	  with	   rDNA	   regulatory	   activities	   (e.g.,	  NoRC,	  
B-­‐WICH)	  might	  also	  impact	  on	  rDNA	  transcription35.	  
Recent	   studies	   provide	   direct	   evidence	   that	   SIRT7	   is	   important	   for	   efficient	  
protein	  translation	  and	  implicate	  additional	  molecular	  mechanisms	  (Figure	  3B).	  
SIRT7-­‐depleted	  cells	  have	  substantially	  reduced	  rates	  of	  protein	  synthesis,	  and	  
a	  functional	  network	  analysis	  of	  the	  SIRT7	  interactome	  identified	  several	  SIRT7-­‐
enriched	   factors	   with	   tight	   links	   to	   ribosome	   dynamics	   and	   protein	  
translation57.	   For	   example,	   SIRT7	   interacts	   with	   mTOR	   and	   the	   TFIIIC2	  
transcription	   factor,	   which	   control	   PolIII-­‐mediated	   synthesis	   of	   transfer	   RNA	  
(tRNA).	   In	   addition,	   SIRT7	   interacts	   with	   multiple	   ribosomal	   proteins,	   which	  
might	  directly	   influence	  ribosome	  function.	  The	  effects	  of	  SIRT7	  on	  alleviating	  
ER	  stress	  during	  the	  UPR,	  described	  above,	  may	  also	  contribute	  to	  promoting	  
efficient	  protein	  translation.	  Indeed,	  a	  reduction	  in	  active	  polysomal	  ribosomes	  
is	  characteristic	  of	  ER	  stress58,	  and	  is	  observed	  in	  SIRT7-­‐deficient	  cells46.	  
Together,	  this	  body	  of	  work	  has	  identified	  SIRT7	  as	  a	  global	  regulator	  of	  diverse	  
aspects	   of	   ribosome	   biogenesis	   and	   protein	   translation.	   Reprogramming	   of	  
cellular	  metabolism	  and	  biosynthetic	  machinery	  towards	  anabolic	  processes	  is	  
crucial	  to	  fuel	  the	  unlimited	  cell	  growth	  and	  division	  of	  cancer	  cells59.	  Increased	  
ribosome	   biogenesis	   and	   rates	   of	   protein	   synthesis	   are	   required	   for	   the	  
elevated	   levels	   of	   cell	   proliferation	   in	   cancer,	   and	   this	   likely	   constitutes	   one	  
general	  paradigm	  through	  which	  SIRT7	  impacts	  on	  cancer	  biology53.	  
	  
	  
1.2.3.	  SIRT7	  modulation	  for	  epigenetic	  cancer	  therapy	  
Genome-­‐wide	   loss	   of	   epigenetic	   stability	   is	   a	   common	   feature	   of	   diverse	  
tumors	   and	   plays	   a	   significant	   role	   in	   cancer	   development60,	   but	   unlike	   DNA	  
mutations,	  which	  are	  permanent,	  epigenetic	  changes	  are	  potentially	  reversible.	  
Because	  of	  its	  effects	  on	  the	  chromatin	  landscape	  and	  malignant	  phenotypes	  of	  
cancer	   cells,	   SIRT7	   is	   a	   promising	   target	   for	   epigenetic	   cancer	   therapy.	  
Moreover	   elevated	   SIRT7	   expression	   has	   been	   observed	   in	   multiple	   human	  
cancer	   tissues,	   including	   prostate,	   hepatocellular,	   breast,	   thyroid,	   and	   other	  
carcinomas34;	  45;	  61;	  62.	  Analysis	  of	  large	  HCC	  patient	  cohorts	  revealed	  that	  SIRT7	  
is	  overexpressed	  by	  >1.8	  fold	  (p<0.0001)	  in	  cancer	  tissues	  compared	  to	  normal	  
controls45,	   and	   in	  microarray	  analyses,	   relative	  SIRT7	  expression	   increased	  2-­‐,	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3.5-­‐,	  and	  4.5-­‐	  fold	  in	  tumors	  of	  increasing	  grade	  (G1-­‐3),	  respectively,	  compared	  
to	   premalignant	   samples	   (p-­‐values	   <0.05,	   0.001,	   0.001)45.	   These	   observations	  
strongly	   suggest	   that	  up-­‐regulation	  of	  SIRT7	   in	  cancer	  cells	  may	  contribute	   to	  
the	  malignant	  phenotype	  of	  human	  patient	  tumors.	  
On	   the	   other	   hand,	   it	   will	   be	   important	   for	   future	   translational	   studies	   to	  
determine	   whether	   pleiotropic	   and	   potentially	   cell	   type-­‐specific	   functions	   of	  
SIRT7	   might	   influence	   overall	   cancer	   incidence	   and	   tumor	   progression	   in	  
unexpected	   ways.	   For	   example,	   it	   is	   still	   unclear	   how	   SIRT7	   impacts	   on	   the	  
process	   of	   oncogenic	   transformation	   itself.	   Indeed,	   in	   early	   stages	   of	   cancer	  
initiation	   in	   premalignant	   cells,	   it	   is	   possible	   that	   SIRT7	   might	   have	   tumor	  
suppressive	  effects.	  This	  could	  occur	  through	  its	  repression	  of	  oncogenic	  Myc-­‐
dependent	  genes	  or	  other	  SIRT7	  gene	  targets	  that	  have	  not	  yet	  been	  identified.	  
The	   tools	   are	   now	   available	   to	   ask	   how	   SIRT7	   activity	   influences	   both	   the	  
efficiency	   of	   oncogenic	   transformation	   of	   primary	   human	   cells,	   and	   the	  
chromatin	  landscape	  of	  H3K18Ac	  and	  gene	  expression	  programs	  in	  these	  cells	  
both	  prior	  to	  and	  during	  induction	  of	  cellular	  transformation.	  
It	   has	   been	   also	   speculated	   that	   SIRT7	   might	   have	   differential	   effects	  
depending	   on	   the	   particular	   genetic	   elements	   that	   underlie	   neoplastic	  
transformation	   in	   specific	   tumors53,	   and	   this	   can	   be	   modeled	   in	   pre-­‐clinical	  
studies	  using	  cellular	  transformation	  assays	  in	  primary	  human	  cells	  and	  mouse	  
tumor	  models63.	   For	  example,	  given	   its	   functional	   interplay	  with	  MYC-­‐,	  ELK4-­‐,	  
and	   E1A-­‐dependent	   epigenetic	   programs,	   SIRT7	   activity	  might	   be	   particularly	  
important	  for	  neoplastic	  transformation	  programs	  and	  tumors	  associated	  with	  
these	  factors.	  Finally,	  the	  effects	  of	  SIRT7	  on	  spontaneous	  tumor	  development	  
in	   mice	   are	   not	   yet	   known.	   SIRT7-­‐deficient	   mice	   have	   been	   reported	   to	   die	  
from	  causes	  unrelated	  to	  cancer	  at	  seven	  months	  of	  age51,	  precluding	  analysis	  
of	  long-­‐term	  tumor	  incidence.	  However,	  a	  different	  SIRT7-­‐mutant	  mouse	  strain	  
does	  not	  show	  this	  premature	  lethality46,	  and	  these	  mice	  should	  be	  studied	  for	  
tumor	  development	  and	  survival.	  
The	   possibility	   of	   SIRT7	   inactivation	   as	   a	   pharmacologic	   strategy	   in	   cancer	  
therapy	  is	  complicated	  by	  evidence	  that	  SIRT7	  might	  have	  beneficial	  effects	  on	  
human	  health.	  Knockout	  mice	  lacking	  SIRT7	  develop	  degenerative	  pathologies	  
associated	   with	   aging,	   such	   as	   kyphosis,	   loss	   of	   subcutaneous	   fat,	   and	  
degenerative	   cardiac	   hypertrophy51.	   Moreover,	   the	   increased	   ER	   stress	   in	  
SIRT7-­‐deficient	   mice	   leads	   to	   fatty	   liver	   pathology,	   which	   in	   humans,	  
predisposes	   to	   cirrhosis	   and	   hepatocellular	   carcinoma46.	   ER	   stress	   is	   also	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implicated	   in	   other	   disease	   processes,	   from	   pancreatic	   beta	   cell	   failure	   and	  
insulin	   resistance	   to	   neurodegeneration.	   It	   will	   be	   important	   to	   determine	  
whether	  SIRT7	  activity	  influences	  the	  spontaneous	  or	  induced	  development	  of	  
these	   or	   other	   pathologies	   in	   mice,	   and	   to	   ask	   whether	   SIRT7	   levels	   or	  
mutations	   are	   associated	   with	   metabolic	   or	   neurodegenerative	   disease	   in	  
human	  patients.	  In	  addition,	  the	  transcriptional	  programs	  that	  are	  regulated	  by	  
SIRT7	  in	  the	  context	  of	  normal	  human	  physiology	  have	  not	  yet	  been	  examined	  
systematically.	  An	  important	  goal	  for	  future	  work	  will	  be	  to	  carry	  out	  genomic	  
studies	   of	   the	   chromatin	   landscape	   of	   SIRT7	   binding	   in	   non-­‐cancer	   cells	   and	  
mammalian	  tissues,	  and	  the	  effects	  of	  SIRT7	  activity	  on	  H3K18Ac	  patterns	  and	  
gene	   expression.	   Finally,	   it	   might	   be	   possible	   “dial	   down”	   SIRT7	   activity	  
pharmacologically	   to	   levels	   that	  might	   attenuate	   cancer	   progression,	  without	  
being	   sufficient	   to	   induce	   the	  disease	  processes	  observed	   in	  mice	   completely	  
lacking	   SIRT7.	   Thus,	   development	   of	   compounds	   that	   can	   modulate	   SIRT7	  
activity	  will	  be	  instrumental	  in	  examining	  these	  questions.	  
Several	   features	   of	   SIRT7	   suggest	   that	   chemical	   modulators	   of	   SIRT7	   activity	  
could	  be	  designed	   to	  have	   relatively	  high	   levels	  of	   biological	   specificity.	   First,	  
cross-­‐reactivity	   of	   SIRT7	  modulators	  with	   other	  mammalian	   sirtuins	  might	   be	  
minimized	   by	   taking	   advantage	   of	   unique	   features	   of	   SIRT7’s	   structure	   and	  
enzymatic	  mechanism.	  The	  conserved	  catalytic	  domains	  of	  sirtuins	  are	  flanked	  
by	  variable	  N-­‐	  and	  C-­‐	  terminal	  extensions.	  Within	  the	  conserved	  domain,	  SIRT7	  
is	  only	  ~40%	  similar	  to	  its	  closest	  mammalian	  family	  member	  SIRT6,	  and	  <30%	  
similar	  to	  the	  others.	  In	  addition,	  the	  non-­‐conserved	  N-­‐	  and	  C-­‐	  terminal	  regions	  
have	   been	   shown	   in	   other	   sirtuins	   to	   influence	   catalytic	   activity	   and	   contain	  
sequences	   that	   are	   bound	   by	   endogenous	   and	   chemical	   regulators64;	   65;	   66.	  
Development	  of	  compounds	  that	  target	  these	  unique	  regions	  of	  SIRT7	  might	  be	  
a	   promising	   strategy.	   Similarly,	   SIRT7	   gene	   regulatory	   activity	   depends	   on	  
interactions	   with	   specific	   binding	   partners	   (e.g.,	   MYC,	   ELK4),	   and	   such	  
interactions	   might	   be	   selectively	   targeted	   pharmacologically	   to	   enable	  
pathway-­‐specific	   modulation	   of	   SIRT7	   function.	   The	   identification	   of	   distinct	  
substrates	  of	   SIRT7	  also	   suggests	   the	  possibility	  of	   substrate-­‐selective	  activity	  
modulation,	   which	   has	   recently	   been	   demonstrated	   for	   SIRT1-­‐activating	  
compounds	  (STACs)67;	  68.	  
Finally,	  there	  are	  indications	  that	  SIRT6	  and	  SIRT7	  are	  unusual	  among	  Sirtuins	  in	  
requiring	  activation	  by	  endogenous	  regulators	   for	  efficient	  catalytic	  activity	   in	  
cells,	   and	   such	   regulatory	   mechanisms	   might	   offer	   additional	   useful	   drug	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targets.	   This	   notion	   is	   supported	   by	   the	   observations	   that	   purified	   SIRT6	   and	  
SIRT7	  proteins	  have	  relatively	  weak	  deacetylase	  activity	  on	  peptide	  substrates	  
in	   vitro,	   despite	   the	   clear	   importance	  of	   their	   enzymatic	   activities	   for	   cellular	  
and	   whole	   organism	   physiology69.	   For	   SIRT6,	   the	   efficiency	   of	   histone	  
deacetylation	   can	   be	   stimulated	   ~35-­‐fold	   by	   certain	   free	   fatty	   acids	   (FFAs)25.	  
The	   sensitivity	   of	   SIRT6	   to	   FFA	   activation	   results	   from	   structural	   features	   of	  
SIRT6	   that	  may	   be	   shared	  with	   SIRT7	   but	   not	   other	  mammalian	   sirtuins.	   For	  
example,	   the	   low	   intrinsic	   activity	   of	   SIRT6	   enzyme	   is	   proposed	   reflect	   an	  
unusually	   “splayed”	   conformation	   that	   binds	   acetylated	   substrate	   poorly69.	  
Binding	   of	   FFAs	   to	   SIRT6	   can	   induce	   a	   conformational	   change	   to	   a	   more	  
enzymatically	   active	   structure25.	   The	   unusual	   conformation	   of	   SIRT6	   is	   partly	  
due	   to	   its	   lack	   of	   a	   conserved	   helix	   bundle	   region	   that	   forms	   important	  
structural	  contacts	  in	  most	  other	  sirtuins69.	  Although	  the	  structure	  of	  SIRT7	  has	  
not	   yet	   been	   characterized,	   predictions	   based	   on	   sequence	   comparisons	  
indicate	   that	   SIRT7	   also	   lacks	   this	   domain69.	   It	   remains	   to	   be	   shown	  whether	  
SIRT7	  requires	  activation	  by	  FFAs,	  but	  if	  so,	  this	  regulation	  would	  provide	  a	  link	  
of	   SIRT7	   activity	   to	   metabolic	   conditions	   that	   might	   be	   targeted	   through	  
pharmacologic	  or	  dietary	  regimens.	  Structural	  and	  biochemical	  studies	  of	  SIRT7	  
in	  this	  context	  should	  provide	  invaluable	  insights	  into	  how	  the	  binding	  by	  FFAs	  
might	  be	  exploited	  for	  therapeutic	  strategies.	  
In	  conclusion,	  mammalian	  sirtuins	  have	  been	  the	  subject	  of	  much	  excitement	  
as	   potential	   therapeutic	   targets	   for	   treating	   aging-­‐related,	   metabolic,	   and	  
neurodegenerative	   disease.	   A	   large	   effort	   has	   focused	   on	   STACs,	  which	   have	  
numerous	  beneficial	  health	  effects	   in	  mice.	  The	   selectivity	  of	  STACs	   for	  SIRT1	  
highlights	   the	   structural	   differences	   among	   sirtuins	   and	   the	   possibility	   of	  
sirtuin-­‐selective	   targeting68;	   70;	   71.	   Several	   chemically	   diverse	   small	   molecule	  
inhibitors	   of	   Sirtuins	   also	   have	   therapeutic	   potential	   and	   varying	   degrees	   of	  
specificity70;	  71;	  72.	  By	  contrast	  to	  other	  Sirtuins,	  SIRT7	  has	  not	  been	  amenable	  to	  
screens	   for	   small	   molecule	   modulators,	   because	   it	   does	   not	   efficiently	  
deacetylate	  the	  substrates	  used	  in	  such	  screens,	  and	  its	  physiologic	  substrates	  
were	  only	  recently	  discovered34;	  36.	  Thus,	  a	  major	  barrier	  in	  the	  field	  has	  finally	  
been	  overcome,	  and	   it	   should	  now	  be	  possible	   to	  design	   strategies	   to	   screen	  
for	   SIRT7-­‐specific	   modulating	   compounds.	   Thus,	   these	   are	   early	   days	   for	  
conceptualizing	   the	   translation	   of	   SIRT7	   biology	   into	   clinical	   applications.	  
Current	  findings	  suggest	  that	  pharmacologic	  inhibition	  of	  SIRT7	  might	  allow	  for	  
simultaneous	   attack	   on	   both	   the	   epigenetic	   programming	   and	   metabolic	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machinery	   of	   cancer	   cells	   that	   support	   tumor	   progression.	   However,	   deeper	  
understanding	  of	  SIRT7	  biology	  at	  the	  molecular	  and	  physiologic	   levels	  will	  be	  
essential	  for	  elucidating	  the	  potential	  therapeutic	  benefits	  and	  detrimental	  side	  




Figure	  3.	   	  Molecular	  pathways	  of	  SIRT7	  and	  their	  known	  or	  predicted	  effects	  on	  cancer	  cell	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biology.	  Question	  marks	   indicate	  connections	  that	  are	  predicted	  but	  not	  yet	  demonstrated	  
experimentally	  (Paredes	  S,	  Villanova	  L	  and	  Chua	  KF.	  Clin	  Cancer	  Res	  2014).	  
	  
	  
1.3.	  The	  tumor	  metastatic	  cascade	  
As	   the	   culprit	   behind	  most	   cancer-­‐related	   deaths,	   metastasis	   is	   the	   ultimate	  
challenge	   in	   our	   effort	   to	   fight	  cancer	   as	   a	   life-­‐threatening	   disease.	   Overt	  
metastasis	  is	  the	  end	  result	  of	  a	  multistep	  process	  that	  involves	  dissemination	  
of	   tumor	   cells	   to	   distant	   organs	   and	   subsequent	   adaptation	   to	   foreign	   tissue	  
microenvironments.	   The	   explosive	   growth	   of	  metastasis	   research	   in	   the	   past	  
decade	   has	   yielded	  an	   unprecedented	   wealth	   of	   information,	   and	   many	  
traditional	  notions	  have	  been	  challenged.	  	  
The	   metastatic	   propensity	   of	   a	   given	   tumor	  is	   influenced	   by	   both	   genetic	  
mutational	   events	   and	   cell	   of	   origin.	   The	   same	   target	   cell	   hit	   by	   different	  
oncogenic	   driver	   mutations	   can	   give	   rise	   to	   tumors	   with	   distinct	   metastatic	  
potential.	  However,	  more	   recent	   studies	  have	   revealed	   that	   the	   cell	   of	  origin	  
also	   contributes	   to	   the	   malignancy	   of	   a	   tumor.	   Indeed,	   the	   same	   oncogenic	  
alterations,	  when	  occurring	  in	  cells	  of	  different	  lineages	  or	  at	  different	  stages	  of	  
differentiation,	  may	  lead	  to	  tumors	  with	  distinct	  metastatic	  behaviors.	  	  
In	  contrast	  to	  the	  conventional	  model	  that	  metastasis	  is	  a	  late	  event	  in	  tumor	  
progression,	   increasing	   evidence	   suggests	   that	   tumor	   cells	   can	   disseminate	  
from	  the	  earliest	  preneoplastic	   lesions,	  sometimes	  even	  before	  the	  formation	  
of	   overt	   primary	   tumors73.	   In	   patients	   with	   localized	   disease	   such	   as	   ductal	  
carcinoma	  in	  situ,	  disseminated	  tumor	  cells	  (DTCs)	  can	  be	  detected	  in	  the	  bone	  
marrow,	  suggesting	  early	  dissemination	  despite	  the	  lack	  of	  stromal	  invasion	  or	  
even	  overt	  primary	  tumor	  formation.	  Whether	  early	  and	  constant	  shedding	  of	  
DTCs	  occurs	   in	  all	   tumors	  and	  what	   the	   link	   is	  between	   these	  early	  DTCs	  and	  
ultimate	  metastasis	  remain	  unclear.	  	  
Metastatic	   tumor	   cells	   can	   follow	   different	   evolution	   paths.	   According	   to	   a	  
“linear”	  progression	  model,	  the	  heterogeneity	  of	  the	  primary	  tumor	  results	   in	  
clonal	  selection,	  during	  which	  the	  dominant	  clone	  expands	  and	  dominates	  over	  
the	   others,	   with	   additional	   mutational	   changes	   occurring	   within	   the	   clonal	  
population,	   hence	   resulting	   in	   different	   degrees	   of	   tumor	  heterogeneity.	   The	  
acquisition	  of	  metastatic	  competence	  and	  organ	  tropism	  occurs	  predominantly,	  
if	   not	   entirely,	   within	   the	   primary	   tumor.	   When	   disseminated,	   these	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heterogeneous	  cells	  seed	  and	  colonize	  different	  organs.	  Additional	  site-­‐specific	  
subclonal	   changes	   could	   occur	   that	   endow	   these	   DTCs	   with	   additional	  
metastatic	  properties	  that	  are	  needed	  for	  the	  formation	  of	  overt	  metastases.	  In	  
contrast,	  a	  different	  body	  of	  clinical	  evidence	  suggests	  a	  “parallel”	  progression	  
model,	   where	   dissemination	   starts	   early,	   and	   different	   tumor	   cell	   clones	   are	  
seeded	  in	  parallel	  to	  different	  organs.	  These	  DTCs	  remain	  dormant	  or	  develop	  
into	   overt	   metastasis	   after	   considerable	   genetic	   evolution	   that	   occurs	  
independently	  of	  primary	  tumor	  progression.	  
The	   emerging	   concept	   of	   tumor	   “self-­‐seeding”	   has	   also	   extended	   our	  
understanding	   of	   the	   pathological	   impact	   of	   tumor	   dissemination.	   The	  
conventional	   unidirectional	  model	   of	  metastasis	   poses	   that	   tumor	   cells	   leave	  
primary	  sites	  to	  seed	  metastasis	  in	  distant	  sites.	  In	  contrast,	  the	  emerging	  self-­‐
seeding	  hypothesis	  proposes	  that	  circulating	  and	  disseminated	  tumor	  cells	  can	  
return	   to	   the	   primary	   tumor.	   In	   fact,	   the	   supportive	   stroma	   that	   arises	   in	   a	  
primary	   tumor	   and	   contributes	   to	   its	   acquisition	   of	   malignant	   traits	   may	  
intrinsically	   provide	   a	   hospitable	   site	   for	   reseeding	   and	   colonization	   by	  
circulating	  cancer	  cells	  emanating	  from	  metastatic	  lesions.	  This	  model	  suggests	  
that	  tumor	  cells	  may	  recirculate	  from	  a	  distant	  site	  (i.e.	  bone	  marrow)	  back	  to	  
the	  primary	  site	  to	  give	  rise	  to	  recurrent	  tumors74.	  
The	  multistep	   process	   of	   invasion	   and	  metastasis	   has	   been	   schematized	   as	   a	  
sequence	  of	  discrete	  steps,	  often	  termed	  the	  invasion-­‐metastasis	  cascade.	  This	  
depiction	  envisions	  a	   succession	  of	   cell-­‐biologic	   changes,	  beginning	  with	   local	  
invasion,	   then	   intravasation	   by	   cancer	   cells	   into	   nearby	   blood	   and	   lymphatic	  
vessels,	   transit	   of	   cancer	   cells	   through	   the	   lymphatic	   and	   hematogenous	  
systems,	   followed	   by	   escape	   of	   cancer	   cells	   from	   the	   lumina	   of	   such	   vessels	  
into	  the	  parenchyma	  of	  distant	  tissues	  (extravasation),	   the	  formation	  of	  small	  
nodules	   of	   cancer	   cells	   (micrometastases),	   and	   finally	   the	   growth	   of	  
micrometastatic	   lesions	   into	  macroscopic	   tumors,	   this	   last	   step	  being	   termed	  
‘‘colonization’’59	  (Figure	  4).	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1.3.1.	  Tumor-­‐intrinsic	  pathways	  and	  tumor-­‐stroma	  interactions	  	  
This	   multistep	   process	   is	   governed	   by	   both	   tumor-­‐intrinsic	   programs	   and	  
tumor-­‐stroma	  crosstalk.	  	  
Cell-­‐autonomous	   mechanisms	   include	   secretion	   of	   matrix	   metalloproteases	  
(MMPs),	   that	   enable	   the	   tumor	   to	   invade	   into	   the	   stroma	   (local	   invasion)	   by	  
breaking	   down	   the	   basement	   membrane	   and	   the	   extracellular	   matrix.	   In	  
addition,	   MMPs	   can	   release	   cell-­‐surface	   and	   matrix-­‐bound	   latent	   growth	  
factors	   and	   cytokines,	   such	   as	   epidermal	   growth	   factor	   (EGF)	   family	   ligands,	  
tumor	  necrosis	  factor-­‐a	  (TNF-­‐a),	  vascular	  endothelial	  growth	  factor	  (VEGF)	  and	  
RANKL,	   that	   can	   act	   in	   an	   autocrine	   or	   paracrine	   manner	   to	   influence	   cell	  
growth,	   survival	   and	   inflammation75.	   Additional	   molecular	   changes	   enable	  
carcinoma	   cells	   to	   enter	   the	   blood	   circulation	   (intravasation),	   including	  
expression	  of	  adhesion	  molecules	  that	  mediate	  the	  interaction	  with	  endothelial	  
cells	  (integrin	  β1),	  and	  secretion	  of	  factors	  that	  increase	  the	  permeability	  of	  the	  
vasculature	  (TGF-­‐β,	  epiregulin,	  COX2,	  MMP1,	  MMP2,	  MMP3,	  ANGPT2,	  MMP10	  
and	  VEGF).	  Activation	  of	   the	  PI3K-­‐Akt	  pathway	  and	   the	  expression	  of	   surface	  
molecules	  such	  as	  CD47	  promote	  the	  survival	  of	  circulating	  tumor	  cells	  (CTCs)	  
by	  inhibiting	  anoikis	  and	  evading	  macrophage	  phagocytosis	  respectively.	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Cancer	  cells	  corrupt	  resident	  tissue	  cells	  and	  recruited	  stromal	  cells	   to	  form	  a	  
supporting	  tumor	  microenvironment	  (TME)76;	  77	  in	  which	  stromal	  cells	  coevolve	  
with	   tumor	   cells78	   to	   influence	   the	   initial	   dissemination	   and	   subsequent	  
metastatic	   traits	   of	   cancer	   cells	   at	   the	   primary	   tumor	   site,	   and	   create	   a	  
permissive	  niche	   at	   the	  metastatic	   site.	   The	  TME	   in	  metastatic	   lesions	  differs	  
markedly	  from	  that	  of	  a	  primary	  tumor,	  and	  emerging	  evidence	  suggests	  that	  
the	   formation	   of	   a	   receptive	   microenvironment	   preceding	   the	   arrival	   of	  
disseminated	   tumor	   cells	   contributes	   to	   metastasis	   efficiency,	   echoing	   the	  
“seed	   and	   soil”	   hypothesis	   proposed	   by	   Stephen	   Paget	  more	   than	   a	   century	  
ago79.	  The	  stromal	  cells	  increase	  tumor	  dissemination	  through	  paracrine	  signals	  
that	  induce	  the	  mobility,	  invasiveness	  and	  survival	  of	  cancer	  cells,	  such	  as	  TGF-­‐	  
β,	  which	  is	  often	  secreted	  by	  cancer-­‐associated	  fibroblasts	  (CAFs).	  The	  TME	  can	  
exert	   a	  major	   role	   also	   in	   the	   later	   stage	   of	   colonization	   at	  metastatic	   sites.	  
Most	   DTCs	   land	   in	   the	   metastatic	   site	   as	   solitary	   tumor	   cells	   and	   have	   to	  
resume	  growth	  to	  spawn	  a	  new	  colony	  and	  establish	  metastases	  or	  otherwise	  
die	  or	  enter	  dormancy.	  Laboratory	  studies	  have	  led	  to	  two	  proposed	  dormant	  
states:	  “cellular	  dormancy”,	  defined	  as	  the	  growth	  arrest	  of	  solitary	  tumor	  cells,	  
and	   “micrometastasis	   dormancy”,	   which	   is	   achieved	   by	   a	   balance	   of	  
proliferation	   and	   apoptosis	   due	   to	   an	   inability	   to	   recruit	   a	   vascular	   bed	   or	  
overcome	  immunosurveillance.	  Growth	  arrest	  might	  result	  from	  maladaptation	  
of	   solitary	   DTCs	   to	   the	   surrounding	   stroma	   (which	   includes	   normal	   resident	  
tissue	   cells),	   as	   they	   are	   deprived	   of	   the	   appropriate	   adhesive	   and	   signaling	  
interactions	  that	  are	  found	   in	  the	  primary	  tumor.	  Either	  at	  primary	  sites	  or	   in	  
the	   circulation,	   tumor	   cells	   can	   release	   soluble	   factors	   or	   microvesicles	   (i.e.	  
exosomes)	  to	  convert	  incipient	  metastatic	  sites	  into	  compatible	  “premetastatic	  
niches”,	  which	  are	   formed	  by	  bone-­‐marrow-­‐derived	  cells	   (BMDCs)	  before	   the	  
arrival	   of	   DTCs.	   Alternatively,	   DTCs	   may	   occupy	   pre-­‐existing	   physiological	  
niches,	   such	   as	   in	   the	   bone,	   where	   DTCs	   may	   compete	   with	   quiescent	  
hematopoietic	  stem	  cells	  (HSCs)	  for	  their	  niche,	  to	  stay	  in	  a	  stem-­‐like,	  dormant	  
state	  before	  resuming	  expansion	  into	  overt	  metastasis	  through	  interaction	  with	  
bone	  stromal	  cells	  (osteoblasts	  and	  osteoclasts).	  Engagement	  of	  bone	  stromal	  
cells	   by	   cancer	   cells	   often	   leads	   to	   abnormal	   bone	   degradation	   or	   bone	  
building,	   which	   further	   promotes	   metastatic	   tumor	   growth	   through	   factors	  
released	  from	  bone	  stromal	  cells	  or	  the	  bone	  matrix.	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1.3.2.	  Epithelial	  plasticity	  in	  the	  invasion-­‐metastasis	  cascade:	  EMT	  and	  MET	  
As	  carcinomas	  arising	  from	  epithelial	  tissues	  progressed	  to	  higher	  pathological	  
grades	   of	   malignancy,	   reflected	   in	   local	   invasion	   and	   distant	   metastasis,	   the	  
associated	  cancer	  cells	  typically	  developed	  alterations	  in	  their	  shape	  as	  well	  as	  
in	   their	   attachment	   to	   other	   cells	   and	   to	   the	   extracellular	  matrix	   (ECM).	   The	  
best	  characterized	  alteration	  involved	  the	  loss	  by	  carcinoma	  cells	  of	  E-­‐cadherin,	  
a	   key	   cell-­‐to-­‐cell	   adhesion	   molecule.	   By	   forming	   adherens	   junctions	   with	  
adjacent	  epithelial	  cells,	  E-­‐cadherin	  helps	  to	  assemble	  epithelial	  cell	  sheets	  and	  
maintain	  the	  polarity	  and	  quiescence	  of	  the	  cells	  within	  these	  sheets.	  Increased	  
expression	  of	  E-­‐cadherin	  was	  well	  established	  as	  an	  antagonist	  of	  invasion	  and	  
metastasis,	  whereas	  reduction	  of	  its	  expression	  was	  known	  to	  potentiate	  these	  
phenotypes.	   The	   frequently	   observed	   downregulation	   and	   occasional	  
mutational	   inactivation	   of	   E-­‐cadherin	   in	   human	   carcinomas	   provided	   strong	  
support	  for	  its	  role	  as	  a	  key	  suppressor	  of	  this	  hallmark	  capability80;	  81.	  
Additionally,	   expression	   of	   genes	   encoding	   other	   cell-­‐to-­‐cell	   and	   cell-­‐to-­‐ECM	  
adhesion	   molecules	   is	   demonstrably	   altered	   in	   some	   highly	   aggressive	  
carcinomas,	   with	   those	   favoring	   cytostasis	   typically	   being	   downregulated.	  
Conversely,	   adhesion	  molecules	   normally	   associated	   with	   the	   cell	   migrations	  
that	  occur	  during	  embryogenesis	  and	  inflammation	  are	  often	  upregulated.	  For	  
example,	   N-­‐cadherin,	   which	   is	   normally	   expressed	   in	   migrating	   neurons	   and	  
mesenchymal	   cells	   during	   organogenesis,	   is	   upregulated	   in	   many	   invasive	  
carcinoma	  cells.	  	  
A	   developmental	   regulatory	   program,	   referred	   to	   as	   the	   ‘‘epithelial-­‐
mesenchymal	   transition’’	   (EMT),	   has	   become	   prominently	   implicated	   as	   a	  
means	  by	  which	  transformed	  epithelial	  cells	  can	  acquire	  the	  abilities	  to	  invade,	  
to	   resist	   apoptosis,	   and	   to	   disseminate59.	   By	   co-­‐opting	   a	   process	   involved	   in	  
various	  steps	  of	  embryonic	  morphogenesis	  and	  wound	  healing,	  carcinoma	  cells	  
can	   concomitantly	   acquire	   multiple	   attributes	   that	   enable	   invasion	   and	  
metastasis.	   This	   multifaceted	   EMT	   program	   can	   be	   activated	   transiently	   or	  
stably,	   and	   to	   differing	   degrees,	   by	   carcinoma	   cells	   during	   the	   course	   of	  
invasion	  and	  metastasis.	  	  
Contextual	   cues	   from	   the	   tumor-­‐associated	   stroma,	   such	   as	   conditions	   of	  
hypoxia	  and	  inflammation,	  are	  likely	  to	  act	  as	  the	  initial	  trigger	  of	  EMT.	  Indeed,	  
cancer	   cells	   at	   the	   invasive	   front	   of	   certain	   carcinomas	   often	   undergo	   EMT,	  
suggesting	   that	   these	   cancer	   cells	   are	   subject	   to	  microenvironmental	   stimuli	  
distinct	   from	  those	   received	  by	  cancer	  cells	   located	   in	   the	  core	  of	   the	   tumor.	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These	   cells	   are	   more	   exposed	   to	   the	   extracellular	   ligands	   supplied	   by	  
fibroblasts,	   immune	  cells	  and	  mesenchymal	  stem	  cells	  populating	  the	  stroma.	  
TGF-­‐beta,	   WNT	   proteins,	   platelet-­‐derived	   growth	   factors	   (PDGFs)	   and	  
interleukin-­‐6	  (IL-­‐6)	  activate	  and	  maintain	  the	  EMT	  program	  in	  the	  tumor	  cells.	  
Being	  redirected	  away	  from	  suppressing	  cell	  proliferation,	  TGF-­‐beta	  signaling	  is	  
found	  instead	  to	  be	  a	  major	  inducer	  of	  EMT	  during	  cancer	  progression82.	  
	  The	   EMT	  program	  underlies	   all	   the	   steps	   of	   tumor	   dissemination,	   from	   local	  
invasion	   to	   extravasation	   (Figure	   5),	   whereas	   the	   colonization	   requires	   the	  
reverse	  process,	  called	  mesenchymal-­‐to-­‐epithelial	  transition	  (MET).	  During	  this	  
process,	   motile	   undifferentiated	   mesenchymal	   cells	   are	   converted	   into	  
polarized	   epithelial	   cells	   with	   increased	   E-­‐cadherin	   levels.	   In	   fact,	   the	  
mesenchymal	   state	   is	  associated	  with	  growth	  arrest	  and	  disseminated	  cancer	  
cells	   have	   to	   exit	   the	   mesenchymal	   state	   to	   resume	   proliferation	   at	   the	  
metastatic	   sites.	   Therefore,	   at	   incipient	   metastatic	   sites,	   MET	   of	   metastatic	  
tumor	  cells	  could	  occur	  because	  of	  either	  the	  absence	  of	  EMT-­‐inducing	  signals	  
or	   the	   presence	   of	   MET-­‐inducing	   signals,	   provided	   by	   bone	   marrow-­‐derived	  
monocytes	  or	  normal	  resident	  cells.	   It	  has	  to	  be	  clarified	  whether	  MET	  occurs	  
right	  after	  extravasation,	  during	  cellular	  dormancy	  or	  perhaps	  after	  reactivation	  
from	  dormancy.	  However,	  the	  notion	  that	  cancer	  cells	  routinely	  pass	  through	  a	  
complete	  EMT	  program	  is	  likely	  to	  be	  simplistic;	  instead,	  in	  many	  cases,	  cancer	  
cells	   may	   enter	   into	   an	   EMT	   program	   only	   partially,	   thereby	   acquiring	   new	  
mesenchymal	  traits	  while	  continuing	  to	  express	  residual	  epithelial	  traits.	  
	  
	  
Figure	  5.	  Role	  of	  EMT	  in	  all	  the	  stages	  of	  tumor	  dissemination	  (Wan	  L	  et	  al.	  Nat	  Med	  2013).	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1.3.3.	  Regulatory	  networks	  defining	  EMT	  
EMT	  is	  a	  reversible	  reprogramming	  of	  the	  cell,	  defined	  by	  a	  plethora	  of	  changes	  
that	   are	   initiated	   and	   maintained	   by	   several	   regulatory	   circuits.	   So	   far,	   five	  
different	  layers	  of	  regulation	  have	  been	  identified.	  	  
Transcriptional	   control.	   A	   set	   of	   pleiotropically	   acting	   transcriptional	   factors,	  
including	   Snail,	   Slug,	   Twist,	   and	   Zeb1/2,	   orchestrate	   the	   EMT	   and	   related	  
migratory	   processes	   during	   embryogenesis.	   These	   transcriptional	   regulators	  
have	   been	   shown	   in	   experimental	   models	   of	   carcinoma	   formation	   to	   be	  
causally	   important	   for	  programming	   invasion;	   some	  have	  been	   found	  to	  elicit	  
metastasis	   when	   ectopically	   overexpressed59.	   Included	   among	   the	   cell-­‐
biological	   traits	   evoked	   by	   such	   transcription	   factors	   are:	   loss	   of	   adherens	  
junctions	   and	   associated	   conversion	   from	   a	   polygonal/epithelial	   to	   a	  
spindly/fibroblastic	   morphology,	   expression	   of	   matrix-­‐degrading	   enzymes,	  
increased	   motility,	   and	   heightened	   resistance	   to	   apoptosis—all	   traits	  
implicated	   in	   the	   processes	   of	   invasion	   and	   metastasis.	   Several	   of	   these	  
transcription	   factors	   (Snail,	   Slug,	   ZEB1,	   ZEB2,	   E47,	   Brachyury)	   can	   repress	   E-­‐
cadherin	   gene	   expression	   by	   direct	   binding	   to	   the	   CDH1	   promoter,	   thereby	  
depriving	   neoplastic	   epithelial	   cells	   of	   this	   key	   suppressor	   of	   motility	   and	  
invasiveness.	  
Epigenetic	   regulation.	  The	  term	  “epigenetics”	  describes	  the	  mechanisms	  that	  
impose	  cellular	  phenotypes	  without	  concomitant	  changes	   in	   the	  genome	  of	  a	  
cell,	   meaning	   without	   changes	   in	   its	   nucleotide	   sequences.	   More	   recently,	  
however,	  it	  has	  become	  apparent	  that	  epigenetic	  regulation	  is	  achieved	  in	  large	  
part	   by	   the	   covalent	   modification	   of	   DNA,	   specifically	   the	   methylation	   of	  
certain	   cytosine	   residues	   (DNA	   methylation),	   as	   well	   as	   by	   the	   covalent	  
modifications	  of	  the	  histone	  proteins	  that	  form	  DNA-­‐associated	  nucleosomes83.	  
The	   reversibility	   of	   epigenetic	   modifications	   is	   likely	   to	   contribute	   to	   EMT	  
plasticity,	   allowing	   cancer	   cells	   to	   switch	   back	   to	   the	   epithelial	   state	   on	  
colonization	   at	   a	   secondary	   site.	   DNA	   methylation	   on	   CpG	   dinucleotides	   in	  
regulatory	  sequences	  is	  a	  typical	  mechanism	  for	  silencing	  tumor	  suppressors	  in	  
cancer	  cells	  and	  plays	  a	  major	  role	  in	  repressing	  the	  CDH1	  promoter	  in	  invasive	  
breast	   carcinomas84;	   85;	   86.	   Other	   repressive	   epigenetic	   modifications	   include	  
methylation	   and	   deacetylation	   of	   histone	   tails.	   The	   polycomb	   group	   (PcG)	  
proteins	   constitute	   a	   group	   of	   epigenetic	   regulators	   that	   have	   a	   key	   role	   in	  
regulating	   the	   expression	   of	   E-­‐cadherin.	   They	   function	   as	   transcription	  
repressors	  by	  directing	  lineage	  choices	  during	  early	  development	  and	  stem	  cell	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differentiation,	   ensuring	   that	   progenitor	   or	   stem	   cells	   remain	   in	   an	  
undifferentiated	   state.	   The	   PcG	   proteins	   assemble	   with	   other	   scaffolding	  
proteins	   to	   form	  multi-­‐subunit	   polycomb	   repressive	   complexes	   (PRCs),	  which	  
silence	   transcription	   by	   histone	   methylation	   and	   recruitment	   of	   a	   variety	   of	  
additional	   repressors.	   Two	  distinct	   classes	   of	   polycomb	   complexes,	   PRC1	   and	  
PRC2,	   participate	   in	   promoting	   EMT.	   PRC2	   is	   made	   up	   of	   the	   subunits	   EZH2	  
(Enhancer	   of	   Zeste	   homolog	   2)	   and	   SUZ12	   (Suppressor	   of	   Zeste	   12	   homolog)	  
and	   is	   recruited	   by	   Snail	   to	   the	   CDH1	   promoter,	   where	   PRC2	   catalyzes	   the	  
trimethylation	  of	   lysine	  27	  of	  histone	  H3	  (H3K27me3),	  thereby	  silencing	  CDH1	  
transcription.	   Deacetylation	   of	   lysine	   histone	   residues	   is	   an	   additional	  
mechanism	  of	  epigenetic	  repression	  of	  the	  CDH1	  promoter.	  Indeed,	  the	  histone	  
deacetylase	  HDAC1	   and	  HDAC2,	  which	   function	   as	   components	   of	  NuRD,	   are	  
recruited	   to	   the	  CDH1	   promoter	   by	   Snail	   and	   Twist.	   Similarly,	   ZEB1	  has	   been	  
shown	  to	  recruit	  the	  sirtuin	  deacetylase	  SIRT1	  to	  repress	  CDH1	  transcription87.	  
The	   final	   outcome	   of	   epigenetic	  modifications	   depends	   also	   on	   the	   crosstalk	  
between	  different	  histone	  marks	  on	  the	  same	  promoter,	  as	  exemplified	  by	  the	  
case	   of	   “bivalent”	   modifications.	   Coexistence	   of	   both	   a	   repressive	   and	   an	  
activating	  histone	  mark	  on	  the	  same	  promoter	  region	  indicates	  an	  inactive	  but	  
poised	  state.	  Genes	  in	  a	  “bivalent”	  state	  are	  not	  being	  actively	  transcribed	  but	  
are	  poised	  to	  become	  readily	  activated	  in	  response	  to	  a	  signaling	  cue	  that	  leads	  
to	   the	   removal	  of	   the	   repressive	  histone	  mark.	   Therefore,	   bivalent	   genes	   are	  
not	   stably	   repressed	  but	   instead	   remain	   responsive	   to	  dynamic	   regulation	  by	  
certain	  physiologic	  signals.	  The	  bivalent	  configuration	  of	  CDH1,	  ZEB1	  and	  TWIST	  
promoters	   contributes	   to	   the	   epithelial	   plasticity	   of	   cancer	   cells,	   allowing	   for	  
prompt	  adaptation	  to	  signals	  from	  the	  tumor	  microenvironment88.	  
MicroRNAs.	   The	   number	   of	   microRNAs	   associated	   with	   EMT	   is	   becoming	   as	  
extensive	  as	  the	  list	  of	  EMT-­‐related	  transcription	  factors.	  Among	  the	  small	  non-­‐
coding	  RNAs	  that	  promote	  epithelial	  differentiation,	  the	  miR-­‐200	  and	  the	  miR-­‐
34	   families	   appear	   two	  major	   players.	  Major	   targets	   of	   these	  microRNAs	   are	  
the	  EMT-­‐inducing	  transcription	  factors.	  Interestingly,	  both	  miR-­‐200	  and	  miR-­‐34	  
have	   E-­‐boxes	   in	   their	   promoters	   that	   are	   bound	   by	   Snail	   and	   ZEB,	   revealing	  
reciprocal	   feedback	   loops	   between	   epithelium-­‐related	   microRNAs	   and	   EMT-­‐
inducing	  transcription	  factors88.	   In	  addition,	  tumor-­‐suppressive	  microRNAs	  are	  
often	   epigenetically	   repressed	   in	   cancers	   by	  methylation	   of	   their	   promoters.	  
There	   is	   also	   evidence	   for	   microRNAs	   promoting	   the	   transition	   to	   a	  
mesenchymal	   phenotype,	   such	   as	   miR-­‐9	   and	   miR-­‐92a,	   which	   target	   CDH1	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directly.	  
Differential	   splicing.	   Alternative	   pre-­‐mRNA	   splicing	   provides	   an	   additional	  
post-­‐transcriptional	   mechanism	   of	   regulation	   of	   EMT.	   Trans-­‐	   and	   cis-­‐acting	  
elements	   controlling	   both	   epithelium-­‐specific	   and	   mesenchyme-­‐specific	  
splicing	   have	   been	   identified.	   These	   RNA-­‐binding	   proteins	   recognize	   splicing-­‐
enhancer	  and	  splicing-­‐inhibitor	  sequences	   in	  the	  pre-­‐mRNA.	  Exon	   inclusion	  or	  
skipping	  is	  determined	  by	  the	  location	  of	  these	  sequence	  elements	  relative	  to	  
the	  alternatively	   spliced	  exons88.	   For	   instance,	   the	  epithelium-­‐specific	   splicing	  
of	   CTNND1	   (which	   encodes	   p120	   catenin)	   results	   in	   a	   shorter	   isoform	   that	  
promotes	  cell-­‐cell	  adhesion	  by	  stabilizing	  E-­‐cadherin	  at	  the	  plasma	  membrane,	  
whereas	  the	  longer	  mesenchymal	  isoform	  induced	  during	  EMT	  binds	  RHOA	  and	  
attenuates	  its	  activity,	  resulting	  in	  enhanced	  cellular	  invasion.	  Importantly,	  the	  
trans-­‐acting	   elements	   that	   mediate	   epithelium-­‐specific	   splicing	   are	   directly	  
downregulated	  by	  the	  EMT-­‐inducing	  transcription	  factors	  Snail,	  ZEB1	  and	  ZEB2	  
and	  their	  expression	  is	  often	  low	  in	  EMT-­‐like	  cancer	  cell	  lines.	  
Translational	   and	   post-­‐translational	   regulation.	   The	   expression	   of	   EMT-­‐
associated	   transcription	   factors	   can	   be	   controlled	   at	   multiple	   steps	   of	   the	  
translation	  process.	   Internal	  ribosome	  entry	  sites	  (IRES)	   located	   in	  the	  mRNAs	  
of	   SNAI1,	   ZEB2	   and	   TWIST1	   can	   drive	   cap-­‐independent	   translation	   initiation.	  
TGF-­‐beta	   signalling	   can	   re-­‐activate	   the	   translational	   elongation	   of	   EMT-­‐
associated	  transcripts.	   In	  addition,	  EMT-­‐inducing	  transcription	  factors,	  such	  as	  
Snail	   and	   ZEB2,	   undergo	   a	   broad	   range	   of	   post-­‐translational	   modifications,	  
including	  phosphorylation,	  lysine	  oxidation,	  ubiquitylation	  and	  sumoylation88.	  
	  
	  
1.3.4.	  The	  invasion-­‐suppressor	  gene	  E-­‐cadherin	  
Most	  human	  cancers	  originate	  from	  epithelial	  tissue.	  E-­‐cadherin,	  the	  prototype	  
member	   of	   the	   “classical”	   cadherin	   family,	   is	   the	   key	   player	   in	   inducing	   cell	  
polarity	  and	  organizing	  an	  epithelium.	   In	  most,	   if	  not	  all,	   cancers	  of	  epithelial	  
origin,	   E-­‐cadherin-­‐mediated	   cell–cell	   adhesion	   is	   lost	   concomitantly	   with	  
progression	   towards	   tumor	   malignancy.	   Although	   E-­‐cadherin	   expression	   can	  
still	   be	   found	   in	   differentiated	   tumors	   in	   patients,	   there	   is	   an	   inverse	  
correlation	   between	   E-­‐cadherin	   levels,	   tumor	   grade	   and	   patient	   mortality81.	  
The	   loss	   of	   E-­‐cadherin	   function	   during	   tumor	   progression	   can	   be	   caused	   by	  
multiple	   mechanisms.	   Predisposition	   to	   diffuse	   gastric	   cancer	   and	   lobular	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breast	  cancer	  in	  patients	  carrying	  germline	  mutations	  in	  the	  E-­‐cadherin	  gene89;	  
90	   identify	  E-­‐cadherin	  as	  a	  tumor	  suppressor	  gene.	  The	  E-­‐cadherin	  gene	  fulfills	  
the	   criteria	   of	   classical	   tumour	   suppressor	   genes,	   inactivated	   by	   two	   genetic	  
hits	  (Knudson,	  1985).	  In	  fact,	  a	  major	  cause	  of	  E-­‐cadherin	  inactivation	  is	  loss	  of	  
heterozigosity	   (LOH)	   of	   16q22.1,	   a	   chromosomic	   region	   containing	   the	   E-­‐
cadherin	  locus.	  The	  remaining	  allele	  is	  often	  inactivated	  by	  mutations	  scattered	  
throughout	   the	   coding	   region	   or	   by	   epigenetic	   silencing	   owing	   to	   DNA	  
hypermethylation	   of	   the	   promoter91.	   A	   major	   level	   of	   E-­‐cadherin	   regulation	  
consists	   in	   the	   binding	   of	   the	   CDH1	   promoter	   by	   EMT-­‐inducing	   transcription	  
factors,	   as	   discussed	   above	   in	   the	   text.	   Additional	   mechanisms	   that	   can	  
compromise	   E-­‐cadherin	   functionality	   include	   post-­‐translational	   modifications	  
and	  proteolytic	  degradation	  by	  matrix	  metalloproteases	  (MMPs)81.	  
Multiple	   evidence	   has	   shown	   that	   loss	   of	   E-­‐cadherin-­‐mediated	   cell–cell	  
adhesion	   is	   a	   prerequisite	   for	   tumour-­‐cell	   invasion	   and	  metastasis	   formation.	  
Several	   groups	   demonstrated	   that	   expression	   of	   exogenous	   E-­‐cadherin	   in	  
invasive	   tumor	   cell	   lines	   resulted	   in	   a	   reduced	   invasion	   ability	   in	   vitro92;	   93.	  
Accordingly,	   tumorigenic	  cell	   lines	  expressing	  exogenous	  E-­‐cadherin	  produced	  
partially	   differentiated	   tumors	   upon	   subcutaneous	   injection	   in	   SCID	   mice,	  
compared	   to	   the	   undifferentiated	   tumors	   produced	   by	   the	   control	  
transfectants93.	   Further	   in	   vivo	   evidence	   demonstrated	   the	   causal	   role	   of	   E-­‐
cadherin	   loss	   in	  tumor	  progression.	  The	  Rip1Tag2	  mouse	  model	  of	  pancreatic	  
β-­‐cell	   carcinogenesis	   was	   intercrossed	   with	   another	   transgenic	   mouse	   line	  
constitutively	  expressing	  E-­‐cadherin	  in	  pancreatic	  β-­‐cells94.	  Whereas	  the	  single-­‐
transgenic	   Rip1Tag2	  mice	   developed	   tumors	   in	   a	   multi-­‐stage	   tumorigenesis	  	  
process,	   starting	  with	   islet	   hyperplasia,	   benign	   adenoma,	   and	   finally	   invasive	  
carcinoma,	   the	   tumorigenesis	   in	   the	   double-­‐transgenic	  mice	   was	   arrested	   at	  
the	  stage	  of	  adenoma.	  In	  addition,	  intercrossing	  Rip1Tag2	  mice	  with	  transgenic	  
mice	  expressing	  a	  dominant-­‐negative	  form	  of	  E-­‐cadherin	  induced	  early	  invasion	  
and	  metastasis94.	   These	   findings	   showed	   that	   loss	   of	   E-­‐cadherin	   is	   one	   rate-­‐
limiting	   step	   in	   the	   progression	   from	   adenoma	   to	   carcinoma	   and	   the	  
subsequent	  formation	  of	  tumor	  metastases.	  
Further	  studies	  provided	  insight	  into	  the	  molecular	  mechanisms	  underlying	  the	  
invasion-­‐suppressive	  role	  of	  E-­‐cadherin.	  Changes	  in	  the	  expression	  or	  function	  
of	   E-­‐cadherin	   can	   contribute	   to	   tumor	   progression	   not	   only	   by	   altering	   the	  
adhesion	  status	  of	  the	  cell,	  but	  also	  by	  affecting	  cell	  signalling.	  In	  fact,	  whereas	  
the	   extracellular	   portion	   of	   the	   E-­‐cadherin	   molecule	   mediates	   cell-­‐to-­‐cell	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homophylic	  interaction,	  the	  intracellular	  portion	  interacts	  with	  the	  Cytoplasmic	  
Cell-­‐adhesion	  Complex	  (CCC),	  which	  links	  E-­‐cadherin	  to	  the	  actin	  cytoskeleton.	  
The	  CCC	  consists	  of	  α-­‐catenin,	  β-­‐catenin,	  γ-­‐catenin	  and	  p120	  catenin.	  Upon	  loss	  
of	   E-­‐cadherin	   and	   disassembly	   of	   the	   CCC,	   catenins	   are	   released	   and	  
accumulate	   in	   the	  cytoplasm,	  where	   they	  exert	   signaling	   functions	   (Figure	  6).	  
Non-­‐sequestered	  β-­‐catenin	  can	  be	  phosphorylated	  by	  GSK-­‐3β	  and	  degraded	  by	  
the	   ubiquitin-­‐proteasome	   pathway.	   However,	   in	   case	   of	   activated	   Wnt	  
signaling,	   the	   GSK-­‐3β	   activity	   is	   blocked	   and	   β-­‐catenin	   accumulates	   at	   high	  
levels	   in	   the	  cytoplasm.	  Subsequently,	   it	   translocates	  to	  the	  nucleus,	  where	   it	  
binds	   to	   members	   of	   the	   TCF/LEF1	   family	   of	   transcription	   factors	   and	  
modulates	   the	   expression	   of	   target	   genes,	   including	   c-­‐MYC,	   cyclin	   D1,	  
fibronectin,	  MMP7,	   ID2,	   CD44,	  NrCAM,	   axin-­‐2	   (conductin),	   TCF1	   and	   others,	  
which	  are	  mostly	  genes	  implicated	  in	  cell	  proliferation	  and	  tumor	  progression.	  
Another	   signal	   that	   is	   elicited	   by	   loss	   of	   E-­‐cadherin	   function	   might	   involve	  
changes	   in	   the	   organization	   of	   the	   cytoskeleton	   that	   are	   orchestrated	   by	  
members	  of	   the	  RHO	  family	  of	  small	  GTPases.	  Once	   it	   is	  not	  sequestered	  any	  
more	  by	   E-­‐cadherin,	   cytosolic	   p120-­‐catenin	   is	   able	   to	   activate	   small	  GTPases,	  
ultimately	   leading	   to	   formation	   of	   filopodia	   (actin-­‐rich	   spikes	   important	   in	  
defining	   the	   directionality	   of	   movement)	   and	   lamellipodia	   (actin-­‐rich	  
membrane	  ruffles	  at	  the	  leading	  edge	  of	  migrating	  cells).	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Figure	  6.	  Potential	  signalling	  pathways	  affected	  by	  loss	  of	  E-­‐cadherin	  function	  (Cavallaro	  U	  
and	  Christofori	  G,	  Nature	  Rev	  Cancer	  2004).	  
	  
	  
1.3.5.	  SIRT1,	  a	  sirtuin	  player	  in	  EMT	  
SIRT1	   belongs	   to	   the	   sirtuin	   family	   of	   NAD-­‐dependent	   lysine	   deacetylases.	  
SIRT1	  shuttles	  from	  the	  nucleus	  to	  the	  cytoplasm,	  and	  its	  targets	  include	  both	  
histone	   marks,	   such	   as	   H3K9Ac,	   H4K16Ac	   and	   H1K26Ac,	   and	   non-­‐histone	  
proteins,	   such	   as	   p53,	   c-­‐Myc,	   FOXO,	   p300,	   Ku70	   and	  many	   others.	   SIRT1	   up-­‐
regulation	  has	  been	  observed	  in	  most	  solid	  tumors,	  including	  breast,	  prostate,	  
lung,	   colon,	   thyroid,	   gastric,	   liver,	   pancreatic,	   ovarian	   and	   cervical	   cancer95.	  
Current	  evidence	  shows	  that	  SIRT1	  can	  function	  as	  both	  a	  tumor	  promoter	  and	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tumor	   suppressor,	   suggesting	   that	   SIRT1	   might	   play	   a	   dual	   role	   in	   different	  
tissue	   contexts,	   depending	   on	   the	   temporal	   and	   spatial	   distribution	   of	  
upstream	  and	  downstream	  factors96.	  SIRT1	  silencing	  induced	  growth	  arrest	  and	  
apoptosis	   in	   human	   epithelial	   cancer	   cells97.	   Furthermore,	   reduced	   SIRT1	  
expression	   decreased	   the	   chemoresistance	   of	   cancer	   cells	   to	   cisplatin	  
treatment98.	  SIRT1	  can	  deacetylate	  p53	  and	  FOXO	  and	  thereby	  inhibit	  P53-­‐	  and	  
FOXO-­‐mediated	   apoptosis99;	   100.	   However,	   a	   different	   body	   of	   evidence	  
suggests	  that	  SIRT1	  can	  also	  function	  as	  a	  tumor	  suppressor.	  No	  tumorigenesis	  
has	  been	  reported	  in	  several	  transgenic	  mouse	  stains	  designed	  to	  overexpress	  
SIRT1101;	   102.	   SIRT1	   was	   found	   to	   inhibit	   by	   deacetylation	   the	   function	   of	   NF-­‐
kB103	  and	  c-­‐Myc104,	  both	  major	  players	  in	  tumor	  progression.	  
Recent	   studies	   have	   revealed	   a	   controversial	   role	   for	   SIRT1	   in	   the	   epithelial-­‐
mesenchymal	   transition	   (EMT).	   SIRT1	   depletion	   led	   to	   the	   increase	   of	   E-­‐
cadherin	  and	  other	  epithelial	  markers	  and	  decrease	  of	  mesenchymal	  markers	  
in	  prostate	  cancer	  cell	  lines,	  ultimately	  leading	  to	  reduced	  cell	  migration	  in	  vitro	  
and	   metastatic	   ability	   in	   vivo87.	   This	   study	   pointed	   out	   SIRT1	   as	   a	   negative	  
regulator	  of	  E-­‐cadherin	  transcription,	  being	  recruited	  to	  the	  CDH1	  promoter	  via	  
the	   EMT-­‐inducing	   transcription	   factor	   ZEB187.	   In	   fact,	   ZEB1-­‐depleted	   cells	  
showed	   less	   recruitment	   of	   SIRT1	   and	   RNA	   PolII	   to	   the	   CDH1	   promoter,	  
together	  with	  decreased	  acetylation	  of	  lysine	  9	  of	  histone	  H3	  (H3K9).	  However,	  
more	  direct	  evidence	   is	  needed	   to	   clarify	  whether	   the	  decrease	   in	  H3K9Ac,	  a	  
histone	   mark	   of	   transcriptionally	   active	   chromatin,	   is	   dependent	   on	   SIRT1	  
deacetylase	  activity.	  The	  EMT-­‐promoting	  role	  of	  SIRT1	  has	  been	  supported	  also	  
by	   the	   finding	   that	   SIRT1	   is	   a	   target	   of	   miR-­‐200a,	   and	   SIRT1	   expression	   is	  
upregulated	   upon	   activation	   of	   TGF-­‐beta	   signaling	   in	   breast	   cancer	   cells105.	  
Intriguingly,	  a	  different	  body	  of	  evidence	  unveiled	  an	  EMT-­‐suppressive	  role	  for	  
SIRT1	   in	   breast	   cancer	   metastasis	   and	   organ	   fibrosis106.	   SIRT1	   depletion	   was	  
found	  to	  decrease	  E-­‐cadherin	  protein	  levels	  in	  primary	  human	  mammary	  cells,	  
but	   a	   different	   mechanism	   of	   SIRT1-­‐mediated	   E-­‐cadherin	   regulation	   was	  
proposed.	   According	   to	   this	   model,	   SIRT1	   inhibits	   Smad4-­‐dependent	  
upregulation	  of	  MMP7,	  induced	  by	  TGF-­‐beta	  signaling.	  Since	  MMP7	  cleaves	  E-­‐
cadherin	  from	  the	  cell	  surface,	  SIRT1	  preserves	  the	  integrity	  of	  the	  Cytoplasmic	  
Cell-­‐adhesion	  Complex	   that	   sequesters	  β-­‐catenin,	   preventing	   its	   translocation	  
to	   the	   nucleus	   and	   thus	   the	   activation	   of	   the	   EMT-­‐induced	   transcription	  
program106.	   Similarly,	   a	   suppressive	   role	   for	   SIRT1	   in	   cancer	   metastasis	   was	  
suggested	   by	   the	   finding	   that	   miR-­‐520c	   and	   miR-­‐373	   repressed	   SIRT1	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translation,	  ultimately	  leading	  to	  increased	  expression	  of	  MMP9	  and	  enhanced	  
cell	  migration	  of	  fibrosarcoma	  cells107.	  
In	   conclusion,	   SIRT1	   seems	   to	  have	   a	   dual	   role	   in	   EMT,	   regulating	   E-­‐cadherin	  
expression	  and	  function	  through	  multiple	  mechanisms.	  
	  
	  
1.4.	  Aim	  of	  the	  work	  
SIRT7	  is	  a	  chromatin	  regulatory	  factor	  belonging	  to	  the	  sirtuin	  family	  of	  NAD+-­‐
dependent	  enzymes,	  whose	  members	  play	  pivotal	  roles	  in	  metabolic	  and	  age-­‐
related	   diseases,	   including	   cancer.	   Until	   few	   years	   ago,	   SIRT7	   was	   the	   most	  
puzzling	   sirtuin,	   being	   its	   enzymatic	   activity	   and	   molecular	   targets	   still	  
unknown.	   Exploring	   SIRT7	  molecular	   function	   and	   its	   impact	   in	   aging-­‐related	  
pathologies	  through	  chromatin	  regulation	  has	  been	  one	  major	  focus	  of	  Chua’s	  
lab.	  Recently,	  the	  Chua’s	   lab	  discovered	  that	  SIRT7	   is	  a	  highly	  selective	  H3K18	  
deacetylase,	   which	   stabilizes	   the	   transformed	   phenotype	   of	   cancer	   cells	   and	  
promotes	  tumor	  growth	   in	  vivo.	  These	  findings	  paved	  the	  way	  for	  subsequent	  
studies	  that	  further	  supported	  the	  tumor-­‐promoting	  role	  of	  SIRT7.	  However,	  no	  
evidence	  has	  pointed	  out	   yet	  a	   role	   for	   SIRT7	   in	   the	   regulation	  of	   cancer	   cell	  
invasiveness	  and	  tumor	  metastasis.	  	  
In	   this	   study,	  we	  sought	   to	  determine	  whether	  SIRT7	  has	  a	   role	   in	  promoting	  
the	   migration,	   invasiveness,	   and	   metastatic	   potential	   of	   cancer	   cells.	   We	  
identified	  E-­‐cadherin,	  a	  key	  suppressor	  of	  tumor	  progression,	  as	  a	  novel	  SIRT7	  
target.	  We	  also	  unveiled	  a	  novel	  crosstalk	  between	  two	  chromatin	  regulators	  of	  
the	   sirtuin	   family,	   which	   promotes	   the	   invasive	   and	  metastatic	   properties	   of	  
cancer	   cells.	   Finally,	  we	   showed	   that	   reduction	   of	   SIRT7	   dramatically	   impairs	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2.1.	  Cell	  Culture	  	  
Cells	   were	   grown	   in	   a	   humidified	   tissue	   culture	   incubator,	   at	   37C,	   5%	   CO2	  
atmosphere.	   LNCaP	   and	   PC3	   cells	   were	   maintained	   in	   Dulbecco's	   Modified	  
Eagle	   Medium	   (DMEM)	   supplemented	   with	   10%	   FBS,	   1%	   penicillin-­‐
streptomycin	  and	  1%	  L-­‐glutamine	  (Gibco,	  Invitrogen).	  HT1080	  cells	  were	  grown	  
in	   Advanced	   DMEM	   (Gibco,	   Invitrogen)	   in	   the	   presence	   of	   10%	   FBS	   and	   1%	  
penicillin-­‐streptomycin.	  All	  cells	  were	  obtained	  from	  the	  American	  Type	  Culture	  
Collection	  (Manassas,	  Virginia).	  
	  
2.2.	  Plasmids	  
Lentiviral	  plasmids	  pSicoR-­‐puro	  encoding	   shRNAs	   targeting	   SIRT7	  mRNA	  were	  
generated	  as	  previously	  described34.	  Target	  sequences	  were	  as	  follows:	  	  S7KD1,	  
5ʹ′-­‐CACCTTTCTGTGAGAACGGAA-­‐3ʹ′;	   S7KD2,	   5ʹ′-­‐TAGCCATTTGTCCTTGAGGAA-­‐3ʹ′.	  
As	   a	   control	   for	   transduction	   we	   used	   the	   pSicoR-­‐puro	   empty	   vector.	   The	  
human	   SIRT7	  H187Y	   expression	   retroviral	   vector	   pBabe-­‐puro	   and	   the	   3XFlag-­‐
tagged-­‐SIRT1	   WT	   and	   H355Y	   mutant	   expression	   vectors	   were	   generated	   as	  
previously	   described9.	   As	   a	   control	   for	   transduction	  we	   used	   the	   pBabe-­‐puro	  	  
and	  the	  3XFlag-­‐puro	  empty	  vectors.	  
	  
2.3.	  Transwell	  invasion	  assay	  
The	   assay	   was	   performed	   according	   to	   BD	   BioCoatTM	   manufacturer’s	  
instructions.	   Briefly,	   medium	   containing	   10%	   FBS	   as	   a	   chemoattractant	   was	  
added	   to	   the	  wells	   of	   a	   24-­‐well	   plate.	   The	  Matrigel	   invasion	   chambers	  were	  
transferred	  to	  the	  wells	  containing	  the	  chemoattractant	  using	  sterile	  forceps.	  A	  
suspension	   of	   10^4	   HT1080	   and	   5*10^4	   PC3	   cells	   in	   serum-­‐free	   media	   was	  
loaded	   into	   the	   chambers.	   Cells	   were	   incubated	   for	   22-­‐24hr	   in	   a	   humidified	  
tissue	   culture	   incubator,	   at	   37C,	   5%	   CO2	   atmosphere.	   The	   non-­‐invading	   cells	  
were	  removed	  by	  scrubbing	  with	  a	  cotton	  tipped	  swab	  and	  the	   invading	  cells	  
were	  fixed	  with	  methanol	   for	  2	  minutes	  and	  stained	  with	  crystal	  violet	   for	  10	  
minutes.	  The	  inserts	  were	  dried	  and	  the	  membrane	  was	  photographed	  through	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2.4.	  Wound	  healing	  assay	  
Cells	   were	   grown	   to	   confluent	   monolayers.	   A	   scratch	   was	   then	   made	   using	  
200uL	  tip	  on	  cell	  monolayers.	  Cells	  were	  washed	  once	  each	  with	  PBS	  and	  warm	  
media.	  Cells	  were	   imaged	   immediately	  after	  creating	   the	  wound	  using	  a	   time	  
lapse	  microscope	  every	  15	  minutes	  for	  12	  hr	  for	  HT1080	  cells	  and	  20	  hr	  for	  PC3	  
cells.	  	  
	  
2.5.	  3D	  Matrigel	  assay	  
LDEV	  free	  Matrigel	  basement	  matrix	  (BD	  Biosciences,	  now	  Corning)	  was	  spread	  
evenly	  on	  the	  bottom	  of	  chamber	  slides	  and	  allowed	  to	  solidify	  at	  37°C	  for	  30	  
minutes.	   500	   PC3	   control	   and	   SIRT7	   KD	   cells	  were	   suspended	   in	   2%	  matrigel	  
and	  spread	  over	  the	  matrix.	  Cells	  were	  fed	  every	  3	  days	  with	  fresh	  2%	  matrigel.	  
Images	  were	  taken	  every	  2	  days.	  	  
	  
2.6.	  Phalloidin	  staining	  	  
Cells	  were	  fixed	  with	  4%	  paraformaldehyde	  for	  10	  minutes	  and	  permeabilized	  
with	  0.1%	  with	  Triton-­‐X	  for	  5	  minutes.	  Cells	  were	  stained	  with	  1:100	  dilution	  of	  
the	  F-­‐actin	  probe	  Alexa	  Fluor	  488	  Phalloidin	   (Life	  Technologies).	   Images	  were	  
acquired	  on	  a	  fluorescence	  microscope	  using	  a	  20x	  objective.	  
	  
2.7.	  Co-­‐immunoprecipitation	  and	  Immunoblot	  
Cell	   lysates	   were	   prepared	   as	   described	   previously.	   1	   mg	   of	   total	   protein	  
extract	  was	  used	  for	   immunoprecipitation	  with	  SIRT7	  antibody	  overnight.	  The	  
immunoprecipitated	   complex	   was	   incubated	   with	   Protein	   A/G	   beads	   (Sigma-­‐
Aldrich)	   for	   1	   hour,	   followed	   by	   washing	   6	   times	   with	   a	   250	   mM	   NaCl-­‐
containing	  buffer.	   The	  beads	  were	   incubated	  at	  37°C	   for	  20	  minutes	  and	   the	  
supernatant	  was	   used	   for	  western	   blot	   analysis.	   Flag-­‐co-­‐immunoprecipitation	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2.8.	  Antibodies	  
E-­‐cadherin	  antibody	   (610181)	  was	  purchased	   from	  BD	  Biosciences.	  SIRT1	   (07-­‐
131)	  and	  β-­‐tubulin	  (05-­‐661)	  antibody	  were	  purchased	  from	  Millipore.	  Vimentin	  
antibody	   (V5255)	  was	   purchased	   from	   Sigma.	   The	   rabbit	   polyclonal	   antibody	  
specifically	  recognizing	  SIRT7	  was	  raised	  against	  the	  following	  synthetic	  peptide	  
GWFGRGCTKRTKRKKVT	   and	   the	   affinity-­‐purified	   antibody	   was	   used	   in	   this	  
study	   (ref.	  Michishita	   E,	   2005).	   Acetylated	   lysine	   18	   of	   histone	  H3	   (H3K18Ac)	  
antibody	   (ab1191)	   was	   purchased	   from	   Abcam	   and	   Lamin	   B	   antibody	   (C20)	  
from	  Santa	  Cruz	  Biotechnology.	  
	  
2.9.	  RT-­‐qPCR	  
Total	  RNA	  was	  extracted	  from	  cells	  using	  the	  RNeasy	  kit	   (Qiagen)	  and	  reverse	  
transcribed	  using	  SuperScript	  III	  (Invitrogen)	  and	  oligo(dT)	  primers,	  according	  to	  
the	   manufacturers'	   instructions.	   Quantitative	   real-­‐time	   PCR	   analysis	   was	  
performed	   on	   a	   Roche	   LightCycler	   480	   using	   the	  manufacturer's	   SYBR	  Green	  
system.	   PCR	   primers	   used	   are:	   E-­‐cadherin:	   Forward	   5’-­‐GGTCTGTCAT-­‐
GGAAGGTGCT-­‐3’;	  Reverse	  5’-­‐GATGGCGGCATTGTAGGT-­‐3’.	  DAB2IP:	  Forward	  5ʹ′-­‐
TGGACGATGTGCTCTATGCC-­‐3ʹ′;	  Reverse	  5ʹ′-­‐GGATGGTGATGGTTTGGTAG-­‐3ʹ′.	  Slug:	  
Forward	   5ʹ′-­‐TGTTGCAGTGAGGGCAAGAA-­‐3ʹ′;	   Reverse	   5ʹ′-­‐GACCCTGGTTG	  
CTTCAAGGA-­‐3ʹ′.	   Gapdh:	   Forward	   5’-­‐AGCCACATCGCTCAGACAC-­‐3’;	   Reverse	   5’-­‐
GCCCAATACGACCAAATCC-­‐3’.	  
	  
2.10.	  Tail	  vein	  injection	  
1x106	   control	   and	   SIRT7-­‐KD	   HT1080	   cells	   were	   intravenously	   inoculated	   into	  
SCID	  mice.	  Lungs	  were	  harvested,	  weighted	  and	  imaged	  28	  days	  post-­‐injection.	  	  
	  
2.11.	  Subcutaneous	  injection	  
The	  subcutaneous	  injection	  of	  SIRT7-­‐knockdown	  HT1080	  cells	  in	  SCID	  mice	  was	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3.1.	  SIRT7	  promotes	  cancer	  cell	  migration	  and	  invasion	  
Current	  evidence	  established	  a	  role	  for	  SIRT7	  in	  the	  epigenetic	  maintenance	  of	  
transformed	  phenotypes	  of	  cancer	  cells34.	  To	  investigate	  whether	  SIRT7	  plays	  a	  
role	   in	   the	   regulation	   of	   cancer	   cell	   phenotypes	   in	  more	   advanced	   stages	   of	  
tumor	   progression,	   and	   in	   particular	   in	   the	   invasion-­‐metastasis	   cascade,	   we	  
examined	  the	  effects	  of	  SIRT7	  depletion	  by	  RNA	  interference	  on	  the	  directional	  
migration	  of	  cancer	  cells,	  by	  wound-­‐healing	  assay.	  A	  wound	  was	  created	  in	  cell	  
monolayers	   and	   a	   time-­‐lapse	  microscope	  was	   used	   to	   observe	   cell	  migration	  
until	   the	  wound	  was	  healed.	  SIRT7	  depletion	   impaired	  the	  migration	  ability	   in	  
two	  different	  cancer	  cell	   lines	  (prostate	  carcinoma	  PC3	  cells	  and	  fibrosarcoma	  
HT1080	  cells),	  resulting	  in	  a	  smaller	  healing	  percentage	  as	  compared	  to	  control	  
cells	  (Figure	  1).	  Notably,	  no	  significant	  changes	  in	  proliferation	  were	  observed	  
under	  the	  time	  conditions	  of	  these	  experiments.	  
	  
Figure	  1.	  SIRT7	  depletion	  impairs	  migration	  of	  cancer	  cells	  in	  wound-­‐healing	  assay.	  
	  
	  
We	  next	  asked	  whether	  SIRT7	  depletion	  could	  affect	  cancer	  cell	   invasiveness.	  
To	  address	  this	  question,	  we	  performed	  a	  matrigel-­‐invasion	  assay,	  that	  allows	  
to	  assess	  cell	  invasion	  in	  vitro	  throughout	  an	  ECM-­‐like	  structure	  that	  mimics	  the	  
tissue	  basement	  membrane.	  The	  assay	  scores	  for	  number	  of	  cells	  invading	  from	  
a	   top	   chamber	   through	   the	   membrane	   (Matrigel	   BD	   BiocoatTM)	   towards	   a	  
chemoattractant	   (e.g.	   serum).	   SIRT7-­‐deficient	   PC3	   cells	   showed	   a	   significant	  
reduction	   in	   the	   number	   of	   cells	   invading	   through	   the	   membrane	   matrix	   as	  
	  	  42	  
compared	  to	  control	  cells	   (Figure	  2,	   left	  panel).	  SIRT7	  depletion	  also	   inhibited	  
the	   invasive	   growth	   pattern	   of	   PC3	   cells	   when	   grown	   in	   three-­‐dimensional	  







Figure	  2.	  SIRT7	  depletion	  reduces	   invasiveness	  of	  PC3	  cells.	  SIRT7-­‐deficient	  PC3	  cells	  show	  
reduced invasion ability in Transwell assay (left panel) and impaired growth in 3D culture 
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A	  similar	  phenotype	  was	  observed	  in	  SIRT7-­‐depleted	  HT1080	  cells	  (Figure	  3A).	  
Moreover,	   overexpression	   of	   a	   catalytically	   inactive	   SIRT7	   mutant	   protein	  
(H187Y)	  also	  reduced	  invasiveness,	  consistent	  with	  a	  dominant	  negative	  effect	  
(Figure	  3B).	  Together,	  these	  results	  suggest	  that	  SIRT7	  plays	  an	  important	  role	  





Figure	  3.	  SIRT7	  depletion	  (A)	  or	  overexpression	  of	  H187Y-­‐SIRT7	  catalytic	  mutant	  (B)	  impairs	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3.2.	   SIRT7	   regulates	   the	   expression	   of	   E-­‐cadherin	   and	   other	   EMT-­‐related	  
genes	  
The	  EMT	  program	  plays	  a	  major	  role	  in	  the	  acquisition	  of	  a	  motile	  behavior	  by	  
epithelial	   cancer	   cells.	   As	   mentioned	   above,	   EMT	   induces	   reorganization	   of	  
actin	   cytoskeleton,	   a	   process	   that	   can	   be	   detected	   by	   staining	   for	   F-­‐actin.	  	  
Fluorescent	  staining	  of	  F-­‐actin	  (Phalloidin	  staining)	   in	  SIRT7-­‐depleted	  PC3	  cells	  
revealed	   a	   more	   collapsed	   cytoskeleton	   (Figure	   4A),	   consistent	   with	   the	  
impaired	  migration	  and	   invasion	  ability	  of	  these	  cells.	  Thus,	  we	  reasoned	  that	  
SIRT7	  might	  affect	   the	  motile	  properties	  of	   cancer	  cells	   through	   regulation	  of	  
the	  EMT	  pathway.	  To	  test	  this	  hypothesis,	  we	  assessed	  the	  expression	  of	  EMT-­‐
related	  genes	  in	  SIRT7-­‐depleted	  cells	  by	  RT-­‐qPCR	  analysis.	  	  
A	   strong	   and	  well-­‐established	   network	   of	   cell-­‐to-­‐cell	   contacts	   is	   essential	   for	  
the	  polarity	  and	  functionality	  of	  normal	  epithelium	  and	  greatly	  limits	  the	  ability	  
of	   epithelial	   cells	   to	   move	   or	   migrate.	   E-­‐cadherin	   plays	   a	   major	   role	   in	   the	  
establishment	   of	   these	   homotypic	   adhesion	   junctions,	   and	   its	   transcriptional	  
downregulation	  is	  one	  of	  the	   leading	  events	   in	  the	  epithelial	  dedifferentiation	  
process	   occurring	   during	   EMT108.	   Indeed,	   during	   embryonic	   development,	   E-­‐
cadherin	  expression	  is	  under	  strict	  spatiotemporal	  control	  and	  its	  repression	  is	  
essential	   for	   certain	  morphogenetic	  movements	  within	   the	   embryo,	  many	   of	  
which	  involve	  EMTs.	  The	  EMT	  occurring	  in	  tumors	  of	  epithelial	  origin	  during	  the	  
acquisition	  of	  the	  invasive	  phenotype	  recapitulates	  the	  same	  molecular	  events	  
that	   occur	   in	   the	   embryo,	   including	   loss	   of	   E-­‐cadherin-­‐mediated	   cell-­‐to-­‐cell	  
junctions.	  Notably,	  SIRT7-­‐deficient	  PC3	  cells	  showed	  an	   increase	   in	   the	  mRNA	  
level	  of	  E-­‐cadherin	  (CDH1)	  (Figure	  4B).	  
DAB2IP	   (DAB2	   interacting	   protein)	   is	   a	   tumor	   suppressor	   gene	   whose	   loss	  
promotes	   epithelial-­‐mesenchymal	   transition	   and	   metastasis	   in	   prostate	  
cancer109;	   110.	   DAB2IP	   promoter	   is	   epigenetically	   inactivated	   in	   human	  
prostate110;	  111	  and	  breast112	  cancer	  and	  its	  expression	  inversely	  correlates	  with	  
tumor	   grade	   and	   predicts	   prognosis	   in	   prostate	   cancer110.	   Interestingly,	   we	  
found	   a	   significant	   increase	   in	   DAB2IP	   expression	   in	   SIRT7-­‐depleted	   cells	  
(Figure	  4B).	  
SIRT7	   reduction	   also	   led	   to	   decreased	   expression	   of	   Slug	   (SNAI2),	   a	  
transcription	   factor	   of	   the	   Snail	   family	   that	   represents	   one	   of	   the	   master	  
regulators	   of	   the	   EMT	   program113	   (Figure	   4B).	   In	   addition	   to	   repressing	   E-­‐
cadherin	  by	  direct	  binding	  to	  the	  CDH1	  gene	  promoter114,	  Slug	  orchestrates	  the	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expression	  of	  several	  EMT-­‐related	  genes113,115.	  	  
The	   matrix	   metalloproteinase	   MMP16	   also	   showed	   reduced	   expression	   in	  
SIRT7-­‐depleted	  cells	  (Figure	  4B),	  consistent	  with	  the	  reduced	  invasive	  ability	  of	  
these	  cells.	  In	  fact,	  the	  upregulation	  of	  MMPs,	  normally	  expressed	  in	  activated	  
leukocytes,	  endows	  tumor	  cells	  with	  the	  ability	  to	  breakdown	  the	  extracellular	  
matrix,	   allowing	   tumor	   invasion	   upon	   disruption	   of	   the	   physiological	   tissue	  
barrier	  represented	  by	  the	  basement	  membrane.	  Western	  blot	  analyses	  further	  
confirmed	   upregulation	   of	   E-­‐cadherin	   in	   SIRT7-­‐depleted	   PC3	   cells	   (Figure	   4C)	  
and	  showed	  a	  reduction	  in	  the	  mesenchymal	  marker	  Vimentin,	  an	  intermediate	  





Figure	  4.	  SIRT7	  regulates	  invasion-­‐	  and	  EMT-­‐related	  genes	  in	  PC3	  cells.	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Functional	   perturbations	   of	   E-­‐cadherin	   have	   been	   associated	   with	   the	  
dedifferentiation/aggressiveness	   of	   tumors92;	   116	   and	   even	   implicated	   in	   the	  
transition	   from	   adenomas	   to	   invasive	   carcinomas94.	   Therefore,	   E-­‐cadherin	   is	  
thought	  to	  be	  an	  invasion-­‐suppressor	  gene93;	  117;	  118	  and	  its	  loss	  is	  considered	  to	  
be	   diagnostic	   of	   a	   poor	   clinical	   prognosis.	   We	   asked	   whether	   such	   SIRT7-­‐
mediated	  repression	  of	  E-­‐cadherin	  could	  correlate	  with	  more	  aggressive	  tumor	  
stages.	  To	  this	  purpose,	  we	  looked	  at	  the	  levels	  of	  SIRT7	  and	  E-­‐cadherin	  in	  the	  
more	  aggressive	  prostate	  cancer	  cell	  line	  PC3	  (derived	  from	  a	  bone	  metastasis	  
of	   prostate	   cancer)	   compared	   to	   the	   more	   epithelial	   counterpart	   LNCaP	  
(isolated	   from	   a	   lymph	   node	   metastasis).	   Western	   blot	   analysis	   showed	  
enhanced	  SIRT7	  expression	  and	  concomitant	  reduced	  E-­‐cadherin	   levels	   in	  PC3	  
compared	  to	  LNCaP	  cells	  (Figure	  5A).	  It	  has	  been	  previously	  shown	  that	  global	  
hypoacetylation	   levels	   of	   H3K18	   decrease	   in	   PC3	   compared	   to	   LNCaP40.	   The	  
concomitant	   increase	   in	   SIRT7	   expression	   suggests	   that	   SIRT7	   can	   be	  
responsible	   for	   alteration	   in	   the	   global	   levels	   of	   this	   histone	   mark	   at	   more	  
aggressive	  tumor	  stages.	  
To	  investigate	  the	  possible	  clinical	  relevance	  of	  the	  inverse	  correlation	  between	  
SIRT7	   and	   E-­‐cadherin	   expression,	   we	   analyzed	   several	   metastatic	   prostate	  
tumors	  in	  the	  Oncomine	  human	  cancer	  gene	  expression	  database.	  Surprisingly,	  
we	  found	  that	  most	  of	  the	  tumors	  in	  4	  different	  datasets	  analyzed	  harbored	  a	  
negative	  correlation	  between	  SIRT7	  and	  E-­‐cadherin	  expression	  (Figure	  5B).	  
	  
	  
Figure	   5.	   Inverse	   correlation	   between	   SIRT7	   and	   E-­‐cadherin	   expression	   in	   metastatic	  
prostate	  cancer.	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3.3.	  SIRT7	  cooperates	  with	  SIRT1	  to	  repress	  E-­‐cadherin	  expression	  	  
SIRT1,	   another	   histone	   deacetylase	   member	   of	   the	   Sirtuin	   family,	   has	   been	  
shown	   to	   repress	   E-­‐cadherin	   transcription	   in	   prostate	   cancer	   cells,	   being	  
recruited	  to	  the	  E-­‐cadherin	  promoter	  via	  the	  EMT-­‐inducing	  transcription	  factor	  
ZEB187.	   Intriguingly,	   our	   co-­‐immunoprecipitation	   assay	   showed	   specific	  
interaction	   in	   vivo	   between	   Flag-­‐tagged	   SIRT7	   and	   endogenous	   SIRT1	   and	  
viceversa	   (Figure	   6A-­‐B).	   This	   result	   was	   further	   confirmed	   by	   co-­‐
immunoprecipitation	  of	  the	  endogenous	  	  proteins	  (Figure	  6C).	  
	  
	  
Figure	  6.	  SIRT7	  interacts	  with	  SIRT1	  in	  vivo.	  
	  
In	   order	   to	   investigate	   a	   potential	   interplay	   involving	   both	   Sirtuins	   on	   E-­‐
cadherin	   regulation,	   we	   overexpressed	   SIRT1	   in	   SIRT7-­‐depleted	   cells	   and	  
looked	  at	  E-­‐cadherin	  RNA	  and	  protein	  levels.	  Consistent	  with	  previous	  findings,	  
E-­‐cadherin	   levels	   were	   reduced	   in	   SIRT1-­‐overexpressing	   cells	   (Figure	   7A-­‐B).	  
Interestingly,	   such	  decrease	  was	  observed	   also	  upon	  overexpression	  of	   SIRT1	  
catalytic	   mutant	   (SIRT1	   point	   mutation	   H355Y),	   suggesting	   that	   E-­‐cadherin	  
regulation	   by	   SIRT1	   is,	   at	   least	   in	   part,	   independent	   of	   SIRT1	   deacetylase	  
activity	  (Figure	  7A-­‐B).	  Moreover,	  SIRT1-­‐induced	  E-­‐cadherin	  downregulation	  was	  
blunted	  in	  SIRT7-­‐deficient	  cells	  (Figure	  7A-­‐B),	  suggesting	  that	  SIRT7	  is	  required	  
to	  mediate	  the	  effect	  of	  SIRT1	  on	  E-­‐cadherin	  regulation.	  	  Overall,	  these	  findings	  
suggest	  that	  SIRT1	  represses	  E-­‐cadherin	  expression,	  at	  least	  partially,	  via	  SIRT7.	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Figure	   7.	   SIRT7	   depletion	   blunts	   SIRT1-­‐induced	   E-­‐cadherin	   downregulation	   at	   both	   the	  






3.4.	   SIRT7	   amplification	   or	   overexpression	   correlates	   with	   metastasis	   in	  
cancer	  patients	  
	  
We	   previously	   demonstrated	   that	   SIRT7	   is	   overexpressed	   in	   several	   patient-­‐
matched	   tumor	   samples34.	   Analysis	   of	   publicly	   available	   datasets	   from	  
cBioPortal	  for	  Cancer	  Genomics	  (www.cbioportal.org)	  revealed	  the	  occurrence	  
of	   amplifications	   and	   mutations	   at	   SIRT7	   locus	   in	   multiple	   human	   cancers	  
(Figure	   8A).	   One	   study	   conducted	   on	   61	   prostate	   cancer	   patients119	   showed	  
amplification	   of	   SIRT7	   locus	   exclusively	   in	   tumors	   at	   the	   metastatic	   stage	  
associated	   with	   low	   survival	   status	   (Figure	   8B).	   In	   addition,	   SIRT7	   was	  
significantly	   overexpressed	   in	   the	   tumor	   metastatic	   site	   compared	   to	   the	  
primary	   site	   in	   a	   prostate	   cancer	   dataset	   from	   Oncomine	   (Figure	   8C).	   These	  
findings	   prompted	   us	   to	   investigate	   whether	   SIRT7	   promotes	   metastasis	   in	  
vivo.	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Figure	  8.	  (A)	  Analysis	  of	  several	  datasets	  from	  cBioPortal	  for	  Cancer	  Genomics	  database.	  (B)	  
Analysis	  of	  a	  reported	  mutational	  landscape	  of	  metastatic	  prostate	  cancer	  (Grasso	  CS	  et	  al.)	  
shows	   exclusive	   amplification	   of	   SIRT7	   in	   metastatic	   prostate	   tumor	   patients	   with	   low	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3.5.	  SIRT7	  promotes	  metastasis	  in	  vivo	  
We	  previously	  showed	  that	  SIRT7	  depletion	  impaired	  tumor	  growth	  formation	  
in	   a	  mouse	   xenograft	   assay34.	   Here	  we	   asked	  whether	   SIRT7	   depletion	   could	  
reduce	  the	  formation	  of	  macroscopic	  metastatic	  lesions.	  To	  look	  specifically	  at	  
metastasis	  without	   complications	   from	   tumor	   growth	   changes,	  we	   generated	  
HT1080	  cells	  with	  only	  partial	  depletion	  of	  SIRT7	  (Figure	  9A).	  	  As	  expected,	  we	  
observed	  only	  a	  subtle	  effect	  of	  SIRT7	  reduction	  on	  primary	  tumor	  growth	  in	  a	  
mouse	  xenograft	  experiment	  (Figure	  9B).	  	  Next,	  tail	  vein	  injection	  experiments	  
were	  performed	  with	  the	  same	  cells.	  Mice	  were	  sacrificed	  28	  days	  post-­‐tail	  vein	  
injection	   and	   their	   lungs	   were	   examined	   for	   macro-­‐metastasis	   formation.	  
Figure	  9C	  shows	  significant	  reduction	  in	  the	  lung	  tumor	  burden	  in	  mice	  injected	  
with	   SIRT7-­‐deficient	   cells	   compared	   to	   control	   cells.	   Strikingly,	   the	   effect	   of	  
SIRT7	  reduction	  on	  metastasis	  formation	  is	  much	  more	  dramatic	  than	  on	  tumor	  
growth.	   These	   findings	   demonstrate,	   for	   the	   first	   time,	   that	   SIRT7	   depletion	  
impairs	  metastasis	  formation	  in	  vivo.	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Figure	   9.	   1x106	   HT1080	   cells	   stably	   expressing	   control	   shRNA	   and	   SIRT7	   shRNA	   were	  
intravenously	  inoculated	  into	  SCID	  mice.	  NIC,	  “no	  injection	  control”.	  	  **	  indicates	  significant	  
differences	   between	   the	   sh-­‐control	   group	   	   by	   Welch's	   T	   test.	   #	   indicates	   significant	  
differences	  between	  the	  sh-­‐control	  group	   	  by	  Student's	  T	  test.	   (**	   :	  P<0.005,	  #	   :	  P<0.05	  vs	  
the	  sh-­‐control	  group).	  
	  
Together,	   our	   current	   findings	   expanded	   SIRT7	   role	   in	   tumor	   progression,	  
uncovering	  a	  new	  function	  for	  SIRT7	  in	  promoting	  cancer	  cell	  invasiveness	  and	  
metastatic	  ability	  through	  regulation	  of	  E-­‐cadherin	  expression.	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We	  have	  previously	   shown	   that	  SIRT7	  promotes	  oncogenic	   transformation	  
and	  stabilizes	  transformed	  phenotypes	  of	  cancer	  cells	  through	  deacetylation	  of	  
the	  H3K18Ac	  histone	  mark	  at	  specific	  promoters.	  Here,	  we	  demonstrated	  that	  
SIRT7	   depletion	   reduces	   migration	   and	   invasion	   of	   cancer	   cells	   in	   vitro	   and	  
metastasis	   in	   vivo.	   We	   showed	   that	   SIRT7	   is	   an	   important	   regulator	   of	   the	  
invasion-­‐EMT	  circuitry	  and	   identified	   the	   invasion-­‐suppressor	  gene	  E-­‐cadherin	  
as	  a	  novel	  SIRT7	  target.	  	  
Elevated	  SIRT7	  expression	  was	  detected	  in	  human	  biopsies	  of	  hepatocellular	  
carcinoma	  (HCC)45,	  thyroid62;	  120	  and	  breast	  cancers61	  compared	  to	  their	  normal	  
counterparts,	  and	  correlated	  with	  malignant	  progression.	  In	  fact,	  relative	  SIRT7	  
expression	   increased	   in	   HCCs	   of	   increasing	   grade	   (G1-­‐3),	   compared	   to	  
premalignant	   samples45.	   Similarly,	   SIRT7	   upregulation	   was	   greater	   in	   thyroid	  
carcinomas	   and	   lymph	   node-­‐positive	   breast	   cancers,	   which	   have	   higher	  
recurrence	   and	   poorer	   prognosis61;	   62;	   120.	   This	   evidence	   has	   hinted	   at	   SIRT7	  
involvement	   in	   tumor	   progression,	   suggesting	   that	   SIRT7	  may	   prove	   to	   be	   a	  
good	   marker	   of	   disease	   progression	   and	   tumor	   behavior.	   However,	   the	  
molecular	  mechanisms	  through	  which	  SIRT7	  may	  impact	  on	  tumor	  progression	  
are	  still	  largely	  unknown.	  Our	  current	  work	  has	  uncovered	  a	  regulatory	  role	  for	  
SIRT7	   in	   the	   expression	   of	   EMT-­‐related	   genes	   and	   the	   epithelial	   marker	   E-­‐
cadherin,	   a	   tumor	   suppressor	   gene	   whose	   loss	   has	   been	   associated	   with	  
enhanced	  invasion	  ability	  and	  metastatic	  properties	  in	  multiple	  cancers.	  	  
Interestingly,	   H3K18	   hypoacetylation	   is	   associated	   with	   poor	   prognosis	   in	  
prostate	   cancer40;	   41.	   We	   found	   enhanced	   expression	   of	   SIRT7	   and	   a	  
concomitant	   decrease	   in	   global	   H3K18Ac	   levels	   in	   the	   more	   invasive	   PC3	  
prostate	   cancer	   cells	   compared	   to	   the	   less	   invasive	   counterpart	   LNCaP.	  
Therefore,	  SIRT7-­‐mediated	  H3K18	  hypoacetylation	  may	  be	  an	  indicator	  of	  poor	  
prognosis	   in	   prostate	   cancer.	   This	   hypothesis	   is	   further	   supported	   by	   our	  
analysis	   of	   human	   patient	   samples	   from	   Oncomine	   database,	   showing	   SIRT7	  
overexpression	   in	   the	   metastatic	   sites	   of	   prostate	   tumors	   compared	   to	   the	  
primary	   site.	   To	   further	   explore	   the	   clinical	   implications	   of	   our	   findings,	   I’m	  
planning	  to	  detect	  by	  immunohistochemistry	  SIRT7	  expression	  at	  the	  invading	  
front	  of	  the	  tumor,	  to	  test	  whether	  SIRT7	  is	  upregulated	  in	  vivo	  in	  those	  tumor	  
cells	   that	   lead	   the	   local	   invasion.	   Next,	   I	   would	   like	   to	   assess	  whether	   SIRT7	  
upregulation	   is	   induced	   in	   these	   cells	   in	   response	   to	   cytokines	   released	   from	  
the	  tumor	  microenvironment,	  such	  as	  TGF-­‐beta.	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Furthermore,	  our	  study	  has	  unveiled	  a	  novel	  interplay	  between	  two	  sirtuin	  
histone	   deacetylases,	   SIRT7	   and	   SIRT1,	   in	   the	   regulation	   of	   E-­‐cadherin	  
expression.	   Analysis	   of	   four	   prostate	   metastatic	   datasets	   from	   Oncomine	  
revealed	  an	  inverse	  correlation	  between	  E-­‐cadherin	  and	  SIRT7	  expression.	  We	  
further	   looked	   into	   these	   datasets	   of	   E-­‐cadherin-­‐negative	   tumors	   for	   tumors	  
that	   showed	   SIRT1	   overexpression.	   While	   the	   number	   of	   metastatic	   tumors	  
overexpressing	   SIRT1	   was	   less	   as	   compared	   to	   SIRT7,	   we	   found	   that	   every	  
single	  SIRT1-­‐overexpressing	  tumor	  also	  overexpressed	  SIRT7.	  This	  observation	  
further	   supports	   the	   hypothesis	   that	   SIRT7	   and	   SIRT1	  may	   have	   overlapping	  
roles	   in	   regulation	   of	   metastasis.	   SIRT7-­‐SIRT1	   interaction	   could	   potentially	  
represent	   a	   conserved	   mechanism	   of	   epigenetic	   regulation	   on	   other	   target	  
promoters.	  Our	  observation	  that	  SIRT7	  interacts	  to	  the	  same	  extent	  with	  both	  	  
the	  WT	   form	   and	   the	   catalytic	   mutant	   of	   SIRT1,	   and	   that	   overexpression	   of	  
SIRT1	   catalytic	  mutant	   is	   able	   to	   repress	  E-­‐cadherin	  expression,	   suggests	   that	  
SIRT1	  catalytic	  activity	  is	  dispensable	  for	  CDH1	  repression.	  We	  hypothesize	  that	  
SIRT1	   might	   function	   as	   a	   scaffold	   protein	   in	   recruiting	   SIRT7	   to	   the	   CDH1	  
promoter,	  and	  that	  SIRT7-­‐mediated	  deacetylation	  of	  H3K18	  is	  necessary	  for	  the	  
repressive	   effect.	   However,	   currently	   we	   cannot	   rule	   out	   the	   possibility	   of	   a	  
crosstalk	  between	  the	  two	  histone	  marks	   that	  are	   targets	  of	   the	  two	  sirtuins,	  
H3K18Ac	   and	   H3K9Ac	   respectively.	   By	   carrying	   out	   chromatin	  
immunoprecipitation	   experiments,	   my	   future	   work	   will	   aim	   at	   dissecting	   the	  
molecular	  mechanism	  underlying	  SIRT7-­‐SIRT1	  crosstalk	  at	  the	  CDH1	  promoter.	  
Given	   the	   overexpression	   of	   SIRT7	   in	   several	   aggressive	   forms	   of	   cancer,	  
SIRT7	   is	   a	   promising	   target	   for	   epigenetic	   therapy.	   Many	   HDAC	   inhibitors	  
(HDACi)	   are	   being	   tested	  while	   two	   have	   been	   FDA	  approved	   for	   anti-­‐cancer	  
therapy.	   In	   this	   setting,	   SIRT7	   modulators	   could	   be	   developed	   as	   a	   part	   of	  
combinatorial	   therapy	   with	   SIRT1	   inhibitors	   and	   other	   HDACi.	   Our	   study	  
prompts	  future	  investigations	  into	  the	  role	  of	  SIRT7	  in	  the	  epigenetic	  regulation	  
of	   tumor	   progression,	   in	   order	   to	   exploit	   its	   use	   as	   a	   potential	   therapeutic	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  indicated:	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